RU2017120481A - Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r - Google Patents

Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r Download PDF

Info

Publication number
RU2017120481A
RU2017120481A RU2017120481A RU2017120481A RU2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A RU 2017120481 A RU2017120481 A RU 2017120481A
Authority
RU
Russia
Prior art keywords
stb
sab
b1sc
sgb
sdc
Prior art date
Application number
RU2017120481A
Other languages
English (en)
Other versions
RU2017120481A3 (ru
RU2717454C2 (ru
Inventor
Маркус Хоссбах
Моника КРАМПЕРТ
Ханс-Лотар АРТ
Original Assignee
Ньюровижн Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюровижн Фарма Гмбх filed Critical Ньюровижн Фарма Гмбх
Publication of RU2017120481A publication Critical patent/RU2017120481A/ru
Publication of RU2017120481A3 publication Critical patent/RU2017120481A3/ru
Application granted granted Critical
Publication of RU2717454C2 publication Critical patent/RU2717454C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0085Brain, e.g. brain implants; Spinal cord
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/313Phosphorodithioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103Receptor protein serine/threonine kinase (2.7.11.30)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)

Claims (44)

1. Антисмысловой олигонуклеотид, состоящий из 10-28 нуклеотидов, и, по меньшей мере, два из 10-28 нуклеотидов представляют LNA, и антисмысловой олигонуклеотид способен гибридизоваться с участком гена, кодирующего TGF-RII, или с участком мРНК, кодирующей TGF-RII, где участок гена, кодирующего TGF-RII, или участок мРНК, кодирующей TGF-RII, содержит последовательность TGGTCCATTC (SEQ. ID NO: 4)или последовательность CCCTAAACAC (SEQ. ID NO: 5), или последовательность ACTACCAAAT (SEQ. ID NO: 6), или последовательность GGACGCGTAT (SEQ. ID NO: 7), или последовательность GTCTATGACG (SEQ. ID NO: 8), или последовательность TTATTAATGC (SEQ. ID NO: 9),и антисмысловой олигонуклеотид содержит последовательность, способную гибридизоваться с указанной последовательностью TGGTCCATTC (SEQ. ID NO: 4) или последовательностью CCCTAAACAC (SEQ. ID NO: 5), или последовательностью ACTACCAAAT (SEQ. ID NO: 6), или последовательностью GGACGCGTAT (SEQ. ID NO: 7), или последовательностью GTCTATGACG (SEQ. ID NO: 8), или последовательностью TTATTAATGC (SEQ. ID NO: 9) соответственно, и соли и оптические изомеры указанного антисмыслового олигонуклеотида.
2. Антисмысловой олигонуклеотид по п.1, где антисмысловой олигонуклеотид гибридизуется избирательно только с последовательностью TGGTCCATTC (SEQ. ID NO: 4) или последовательностью CCCTAAACAC (SEQ. ID NO: 5), или последовательностью ACTACCAAAT (SEQ. ID NO: 6), или последовательностью GGACGCGTAT (SEQ. ID NO: 7), или последовательностью GTCTATGACG (SEQ. ID NO: 8), или последовательностью TTATTAATGC (SEQ. ID NO: 9) участка гена, кодирующего TGF-RII, или участка мРНК, кодирующей TGF-RII.
3. Антисмысловой олигонуклеотид по п.1 или 2, где антисмысловой олигонуклеотид имеет длину 12-20 нуклеотидов, и/или где антисмысловой олигонуклеотид имеет гапмерную структуру с 1-5 звеньями LNA на терминальном 3ʹ-конце и 1-5 звеньями LNA на терминальном 5ʹ-конце, и/или где антисмысловой олигонуклеотид содержит фосфат, фосфоротиоат и/или фосфородитиоат в качестве межнуклеотидных связей.
4. Антисмысловой олигонуклеотид по любому из пп.1-3, где антисмысловой олигонуклеотид представлен следующей последовательностью:
5ʹ-N1-GTCATAGA-N2-3ʹ (SEQ. ID NO: 12) или
5ʹ-N3-ACGCGTCC-N4-3ʹ (SEQ. ID NO: 98) или
5ʹ-N5-TTTGGTAG-N6-3ʹ (SEQ. ID NO: 11) или
5ʹ-N 7 -AATGGACC-N 8 -3ʹ (SEQ. ID NO: 100) или
5ʹ-N9-ATTAATAA-N10-3ʹ (SEQ. ID NO: 101) или
5ʹ-N11-TGTTTAGG-N12-3ʹ (SEQ. ID NO: 10) или
где:
N1 представляет: CATGGCAGACCCCGCTGCTC-, ATGGCAGACCCCGCTGCTC-, TGGCAGACCCCGCTGCTC-, GGCAGACCCCGCTGCTC-, GCAGACCCCGCTGCTC-, CAGACCCCGCTGCTC-, AGACCCCGCTGCTC-, GACCCCGCTGCTC-, ACCCCGCTGCTC-, CCCCGCTGCTC-, CCCGCTGCTC-, CCGCTGCTC-, CGCTGCTC-, GCTGCTC-, CTGCTC-, TGCTC-, GCTC-, CTC-, TC- или C-;
N2 представляет: -C, -CC, -CCG, -CCGA, -CCGAG, -CCGAGCC, -CCGAGCCCCC, -CCGAGCCCCCC, -CCGAGCCCCCCAG, -CCGAGCCCCCAGC, -CCGAGCCCCCAGCG, -CCGAGCCCCCAGCGC, -CCGAGCCCCCAGCGCA, -CCGAGCCCCCAGCGCAG, -CCGAGCCCCCAGCGCAGC, -CCGAGCCCCCAGCGCAGCGG или -CCGAGCCCCCAGCGCAGCGG;
N3 представляет: GGTGGGATCGTGCTGGCGAT-, GTGGGATCGTGCTGGCGAT-, TGGGATCGTGCTGGCGAT-, GGGATCGTGCTGGCGAT-, GGATCGTGCTGGCGAT-, GATCGTGCTGGCGAT-, ATCGTGCTGGCGAT-, TCGTGCTGGCGAT-, CGTGCTGGCGAT-, GTGCTGGCGAT-, TGCTGGCGAT-, GCTGGCGAT-, CTGGCGAT-, TGGCGAT-, GGCGAT-, GCGAT-, CGAT-, GAT-, AT- или Т-;
N4 представляет: -ACAGGACGATGTGCAGCGGC, -ACAGGACGATGTGCAGCGG, -ACAGGACGATGTGCAGCG, -ACAGGACGATGTGCAGC, -ACAGGACGATGTGCAG, -ACAGGACGATGTGCA, -ACAGGACGATGTGC, -ACAGGACGATGTG, -ACAGGACGATGT, -ACAGGACGATG, -ACAGGACGAT, -ACAGGACGA, -ACAGGACG, -ACAGGAC, -ACAGGA, -ACAGG, -ACAG, -ACA, -AC или -A;
N5 представляет: GCCCAGCCTGCCCCAGAAGAGCTA-, CCCAGCCTGCCCCAGAAGAGCTA-, CCAGCCTGCCCCAGAAGAGCTA-, CAGCCTGCCCCAGAAGAGCTA-, AGCCTGCCCCAGAAGAGCTA-, GCCTGCCCCAGAAGAGCTA-, CCTGCCCCAGAAGAGCTA-, CTGCCCCAGAAGAGCTA-, TGCCCCAGAAGAGCTA-, GCCCCAGAAGAGCTA-, CCCCAGAAGAGCTA-, CCCAGAAGAGCTA-, CCAGAAGAGCTA-, CAGAAGAGCTA-, AGAAGAGCTA-, GAAGAGCTA-, AAGAGCTA-, AGAGCTA-, GAGCTA-, AGCTA-, GCTA-, CTA-, TA- или A-;
N6 представляет: -TGTTTAGGGAGCCGTCTTCAGGAA, -TGTTTAGGGAGCCGTCTTCAGGA, -TGTTTAGGGAGCCGTCTTCAGG, -TGTTTAGGGAGCCGTCTTCAG, -TGTTTAGGGAGCCGTCTTCA, -TGTTTAGGGAGCCGTCTTC, -TGTTTAGGGAGCCGTCTT, -TGTTTAGGGAGCCGTCT, -TGTTTAGGGAGCCGTC, -TGTTTAGGGAGCCGT, -TGTTTAGGGAGCCG, -TGTTTAGGGAGCC, -TGTTTAGGGAGC, -TGTTTAGGGAG, -TGTTTAGGGA, -TGTTTAGGG, -TGTTTAGG, -TGTTTAG, -TGTTTA, -TGTTT, -TGTT, -TGT, -TG или -T;
N7 представляет: TGAATCTTGAATATCTCATG-, GAATCTTGAATATCTCATG-, AATCTTGAATATCTCATG-, ATCTTGAATATCTCATG-, TCTTGAATATCTCATG-, CTTGAATATCTCATG-, TTGAATATCTCATG-, TGAATATCTCATG-, GAATATCTCATG-, AATATCTCATG-, ATATCTCATG-, TATCTCATG-, ATCTCATG-, TCTCATG-, CTCATG-, TCATG-, CATG-, ATG-, TG- или G-; и
N8 выбран из: -AGTATTCTAGAAACTCACCA, -AGTATTCTAGAAACTCACC, -AGTATTCTAGAAACTCAC, -AGTATTCTAGAAACTCA, -AGTATTCTAGAAACTC, -AGTATTCTAGAAACT, -AGTATTCTAGAAAC, -AGTATTCTAGAAA, -AGTATTCTAGAA, -AGTATTCTAGA, -AGTATTCTAG, -AGTATTCTA, -AGTATTCT, -AGTATTC, -AGTATT, -AGTAT, -AGTA, -AGT, -AG или -A;
N9 представляет: ATTCATATTTATATACAGGC-, TTCATATTTATATACAGGC-, TCATATTTATATACAGGC-, CATATTTATATACAGGC-, ATATTTATATACAGGC-, TATTTATATACAGGC-, ATTTATATACAGGC-, TTTATATACAGGC-, TTATATACAGGC-, TATATACAGGC-, ATATACAGGC-, TATACAGGC-, ATACAGGC-, TACAGGC-, ACAGGC-, CAGGC-, AGGC-, GGC-, GC- или C-;
N10 представляет: -AGTGCAAATGTTATTGGCTA, -AGTGCAAATGTTATTGGCT, -AGTGCAAATGTTATTGGC, -AGTGCAAATGTTATTGG, -AGTGCAAATGTTATTG, -AGTGCAAATGTTATT, -AGTGCAAATGTTAT, -AGTGCAAATGTTA, -AGTGCAAATGTT, -AGTGCAAATGT, -AGTGCAAATG, -AGTGCAAAT, -AGTGCAAA, -AGTGCAA, -AGTGCA, -AGTGC, -AGTG, -AGT, -AG или -A;
N11 представляет: TGCCCCAGAAGAGCTATTTGGTAG-, GCCCCAGAAGAGCTATTTGGTAG-, CCCCAGAAGAGCTATTTGGTAG-, CCCAGAAGAGCTATTTGGTAG-, CCAGAAGAGCTATTTGGTAG-, CAGAAGAGCTATTTGGTAG-, AGAAGAGCTATTTGGTAG-, GAAGAGCTATTTGGTAG-, AAGAGCTATTTGGTAG-, AGAGCTATTTGGTAG-, GAGCTATTTGGTAG-, AGCTATTTGGTAG-, GCTATTTGGTAG-, CTATTTGGTAG-, TATTTGGTAG-, ATTTGGTAG-, TTTGGTAG-, TTGGTAG-, TGGTAG-, GGTAG-, GTAG-, TAG-, AG- или G-,
N12 представляет: -GAGCCGTCTTCAGGAATCTTCTCC, -GAGCCGTCTTCAGGAATCTTCTC, -GAGCCGTCTTCAGGAATCTTCT, -GAGCCGTCTTCAGGAATCTTC, -GAGCCGTCTTCAGGAATCTT, -GAGCCGTCTTCAGGAATCT, -GAGCCGTCTTCAGGAATC,-GAGCCGTCTTCAGGAAT, -GAGCCGTCTTCAGGAA, -GAGCCGTCTTCAGGA,-GAGCCGTCTTCAGG, -GAGCCGTCTTCAG, -GAGCCGTCTTCA, -GAGCCGTCTTC, -GAGCCGTCTT, -GAGCCGTCT, -GAGCCGTC, -GAGCCGT,-GAGCCG, -GAGCC, -GAGC, -GAG, -GA или -G.
5. Антисмысловой олигонуклеотид по любому из пп.1-4, где последние 2-4 нуклеотида на терминальном 5ʹ-конце представляют нуклеотиды LNA, и последние 2-4 нуклеотида на терминальном 3ʹ-конце представляют нуклеотиды LNA, и между нуклеотидами LNA на терминальном 5ʹ-конце и нуклеотидами LNA на терминальном 3ʹ-конце находится, по меньшей мере, 6 последовательных нуклеотидов, представляющих нуклеотиды, которые не являются LNA, или которые представляют нуклеотиды ДНК.
6. Антисмысловой олигонуклеотид по любому из пп.1-5, где нуклеотиды LNA связаны друг с другом через фосфоротиоатную группу или фосфородитиоатную группу, или где все нуклеотиды связаны друг с другом через фосфатную группу или фосфоротиоатную группу, или фосфородитиоатную группу.
7. Антисмысловой олигонуклеотид по любому из пп.1-6, где нуклеотиды LNA выбраны из следующей группы:
Figure 00000001
Figure 00000002
где:
ILʹ представляет -Xʺ-P(=Xʹ)(X-)-;
Xʹ представляет =O или =S;
X- представляет -O-, -OH, -ORH, -NHRH, -N(RH)2, -OCH2CH2ORH, -OCH2CH2SRH, -BH3 -, -RH, -SH, -SRH или -S-;
Xʺ представляет -O-, -NH-, -NRH-, -CH2- или –S-;
Y представляет -O-, -NH-, -NRH-, -CH2- или –S-;
RC и RH независимо друг от друг выбраны из атома водорода и C1-4-алкила.
В представляет азотистое основание, выбранное из следующей группы:
аденин, тимин, гуанин, цитозин, урацил, 5-метилцитозин, 5-гидроксиметилцитозин, N4-метилцитозин, ксантин, гипоксантин, 7-деазаксантин, 2-аминоаденин, 6-метиладенин, 6-метилгуанин, 6-этиладенин, 6-этилгуанин, 2-пропиладенин, 2-пропилгуанин, 6-карбоксиурацил, 5,6-дигидроурацил, 5-пропинилурацил, 5-пропинилцитозин, 6-азаурацил, 6-азацитозин, 6-азатимин, 5-урацил, 4-тиоурацил, 8-фтораденин, 8-хлораденин, 8-бромаденин, 8-иодаденин, 8-аминоаденин, 8-тиоладенин, 8-тиоалкиладенин, 8-гидроксиладенин, 8-фторгуанин, 8-хлоргуанин, 8-бромгуанин, 8-иодгуанин, 8-аминогуанин, 8-тиолгуанин, 8-тиоалкилгуанин, 8-гидроксилгуанин, 5-фторурацил, 5-бромурацил, 5-хлорурацил, 5-иодурацил, 5-трифторметилурацил, 5-фторцитозин, 5-бромцитозин, 5-хлорцитозин, 5-иодцитозин, 5-трифторметилцитозин, 7-метилгуанин, 7-метиладенин, 8-азагуанин, 8-азааденин, 7-деазагуанин, 7-деазааденин, 7-деаза-8-азааденин, 3-деазагуанин, 3-деазааденин, 2-тиоурацил, 2-тиотимин и 2-тиоцитозин.
8. Антисмысловой олигонуклеотид по любому из пп.1-7, имеющий одну из следующих гапмерных структур: 3-8-3, 4-8-2, 2-8-4, 3-8-4, 4-8-3, 4-8-4, 3-9-3, 4-9-2, 2-9-4, 4-9-3, 3-9-4, 4-9-4, 3-10-3, 2-10-4, 4-10-2, 3-10-4, 4-10-3, 4-10-4, 2-11-4, 4-11-2, 3-11-4, 4-11-3.
9. Антисмысловой олигонуклеотид по любому из пп.1-8, где антисмысловые олигонуклеотиды связываются со 100% комплементарностью с мРНК, кодирующей TGF-RII, и не связываются с каким-либо другим участком в транскриптоме человека.
10. Антисмысловой олигонуклеотид, выбранный из следующей группы:
SEQ ID No: Последовательность, 5'-3' 219a Gb 1 sAb 1 sdAsdTsdGsdGsdAsdCsC*b 1 sAb 1 219b Gb 1 Ab 1 dAdTdGdGdAdCC*b 1 Ab 1 220a Tb 1 sGb 1 sAb 1 sdAsdTsdGsdGsdAsdCsC*b 1 sAb 1 sGb 1 220b Tb 1 Gb 1 Ab 1 dAdTdGdGdAdCC*b 1 Ab 1 Gb 1 220c Tb 1 sGb 1 sAb 1 sdAsdTsdGsdGsdAsdCsdC*sAb 1 sGb 1 220d Tb 1 sdGsdA*sdAsdTsdGsdGsdAsdC*sdCsAb 1 sGb 1 220e Tb 1 sGb 1 sdA*sdA*sdTsdGsdGsdA*sdC*sdC*sdAsGb 1 221a Tb 1 sGb 1 sAb 1 sAb 1 sdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 221b Tb 1 Gb 1 Ab 1 Ab 1 dUdGdGdAdCdCAb 1 Gb 1 Tb 1 221c Tb 1 sGb 1 sAb 1 sAb 1 sdTsdGsdGsdAsdCsdC*sAb 1 sGb 1 sTb 1 221d Tb 1 sGb 1 sAb 1 sdAsdTsdGsdGsdA*sdCsdC*sdAsGb 1 sTb 1 221e Tb 1 sGb 1 sdA*sdAsdTsdGsdGsdAsdC*sdCsdAsdGsTb 1 221f Tb 1 sdGsdAsdA*sdTsdGsdGsdAsdCsC*b 1 sAb 1 sGb 1 sTb 1 222a Ab 1 sTb 1 sGb 1 sAb 1 sdAsdTsdGsdGsdAsdCsC*b 1 sAb 1 sGb 1 sTb 1 222b Ab 1 Tb 1 Gb 1 Ab 1 dAsdTsdGsdGsdAsdCsdC*sAb 1 Gb 1 Tb 1 222c Ab 1 Tb 1 dGdA*dAdTdGdGdA*dCC*b 1 Ab 1 Gb 1 Tb 1 222d Ab 4 sTb 4 sGb 4 sdA*sdAsdTsdGsdGsdAsdCsdC*sAbsGb 4 sTb 4 222e Ab 1 sdTsdGsdA*sdA*sdTsdGsdGsdA*sdC*sdC*sdA*sdGsTb 1 222f Ab 2 sTb 2 sGb 2 sdA*sdAsdUsdGsdGsdAsdCsdCsAb 2 sGb 2 sTb 2 222g Ab 4 ssTb 4 ssdGssdAssdAssdTssdGssdGssdAssdCssdCssAb 4 ssGb 4 ssTb 4 223a Ab 1 sTb 1 sGb 1 sAb 1 sdAdTdGdGdAdCdC*sAb 1 sGb 1 sTb 1 sAb 1 223b Ab 1 ssTb 1 ssdGssdAssdAssdTssdGssdGssdAssdCssdCssdAssdGssdTssAb 1 223c Ab 1 dTdGdAdAdTdGdGdAdCdCdAdGdTAb 1 223d Ab 1 sTb 1 sdGsdAsdAsdUsdGsdGsdA*sdCsdCsdAsGb 1 sTb 1 sAb 1 223e Ab 6 Tb 6 Gb 6 dA*dAdTdGdGdAdCdC*dAGb 6 Tb 6 Ab 6 223f Ab 1 Tb 1 dGsdAsdAsdTsdGsdGsdAsdC*sdC*sAb 1 Gb 1 Tb 1 Ab 1 223g Ab 4 sTb 4 sGb 4 sdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsTb 4 sAb 4 223h Ab 1 sTb 1 sGb 1 sAb 1 sdAsdTsdGsdGsdAsdC*sdC*sdAsdGsdTsAb 1 223i Ab 1 ssTb 1 ssdGssdAssdAssdUssdGssdGssdA*ssdCssdCssdAssdGssTb 1 ssAb 1 218y C*b 2 sAb 2 sTb 2 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 2 sGb 2 sTb 2 sAb 2 218z C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdC*sdC*sAb 1 sGb 1 sTb 1 sAb 1 218aa C*b 1 ssAb 1 ssTb 1 ssdGssdAssdAssdTssdGssdGssdAssdCssdCssAb 1 ssGb 1 ssTb 1 ssAb 1 218ab C*b 1 Ab 1 Tb 1 dGsdAsdAsdUsdGsdGsdAsdC*sdC*sAb 1 Gb 1 Tb 1 Ab 1 218ac C*b 1 Ab 1 Tb 1 dGsdA*sdA*sdTsdGsdGsdA*sdCsdCsAb 1 Gb 1 Tb 1 Ab 1 218ad C*b 6 sAb 6 sTb 6 sdGdAdAdTdGdGdAdCdCAb 6 sGb 6 sTb 6 sAb 6 218ae C*b 7 sAb 7 sTb 7 sGb 7 sdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 7 sTb 7 sAb 7 218af C*bs 1 Ab 1 sdUsdGsdAsdAsdUsdGsdGsdUsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 218b C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 218m C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdC*sdC*sAb 1 sGb 1 sTb 1 sAb 1 218n C*b 1 Ab 1 Tb 1 dGsdAsdAsdTsdGsdGsdAsdC*sdC*sAb 1 Gb 1 Tb 1 Ab 1 218o C*b 1 sAb 1 sTb 1 sdGsdA*sdA*sdTsdGsdGsdA*sdCsdCsAb 1 sGb 1 sTb 1 sAb 1 218p C*b 1 sAb 1 sTb 1 sdGsdA*sdA*sdTsdGsdGsdA*sdC*sdC*sAb 1 sGb 1 sTb 1 sAb 1 218q C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdC*sdCsAb 1 sGb 1 sTb 1 sAb 1 218c C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdC*sAb 1 sGb 1 sTb 1 sAb 1 218r C*b 1 Ab 1 Tb 1 dGdAdAdTdGdGdAdCdCAb 1 Gb 1 Tb 1 Ab 1 218s C*b 1 sAb 1 sTb 1 sdGdAdAdTdGdGdAdC*sdC*sAb 1 sGb 1 sTb 1 sAb 1 218t /5SpC3s/C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 218u C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 /3SpC3s/ 218v /5SpC3s/C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 /3SpC3s/ 218ag C*b 1 sAb 1 sTb 1 sdGsdA*sdA*sdUsdGsdGsdA*sdCsdCsAb 1 sGb 1 sTb 1 sAb 1 218ah C*b 4 ssAb 4 ssTb 4 ssdGssdA*ssdA*ssdTssdGssdGssdA*ssdCssdCssdAssdGssTb 4 ssAb 4 218ai C*b 2 ssAb 2 ssTb 2 ssGb 2 ssdAssdAssdTssdGssdGssdAssdCssdCssdAssdGssdTssAb 2 218aj C*b 1 Ab 1 Tb 1 Gb 1 dAdAdUdGdGdAdCdCAb 1 Gb 1 Tb 1 Ab 1 218ak C*b 1 sAb 1 sTb 1 sGb 1 sAb 1 sdA*sdUsdGsdGsdAsdCsdCsdA*sGb 1 sTb 1 sAb 1 218am C*b 1 sAb 1 sdUsdGsdAsdAsdUsdGsdGsdAsdCsC*b 1 sAb 1 sGb 1 sTb 1 sAb 1 218an C*b 6 sAb 6 sTb 6 sGb 6 sdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 6 sTb 6 sAb 6 218ao C*b 7 sAb 7 sTb 7 sdGsdA*sdA*sdUsdGsdGsdAsdCsdCsdA*sGb 7 sTb 7 sAb 7 218ap C*b 4 sAb 4 sTb 4 sGb 4 sdA*sdAsdTsdGsdGsdAsdCsdC*sdAsdGsTb 4 sAb 4 218aq C*b 4 Ab 4 Tb 4 Gb 4 dAdAdTdGdGdAdCdCdAdGTb 4 Ab 4 218ar C*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 1 sTb 1 sAb 1 224a C*b 1 sAb 1 sTb 1 sGb 1 sAb 1 sdAsdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 sTb 1 224b C*b 2 sAb 2 sTb 2 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 2 sGb 2 sTb 2 sAb 2 sTb 2 224c C*b 1 sAb 1 sTb 1 sGb 1 sdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsTb 1 sAb 1 sTb 1 224d C*b 1 sdAsdUsdGsdAsdAsdUsdGsdGsdAsdC*sdC*sAb 1 sGb 1 sTb 1 sAb 1 sTb 1 224e C*b 1 sAb 1 sTb 1 sdGsdA*sdA*sdTsdGsdGsdA*sdC*sdC*sAb 1 sGb 1 sTb 1 sAb 1 sTb 1 224f C*b 1 Ab 1 dTdGdAdAdTdGdGdAdCdCdAGb 1 Tb 1 Ab 1 Tb 1 224g C*b 1 sdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsTb 1 sAb 1 sTb 1 224h C*b 1 Ab 1 Tb 1 Gb 1 Ab 1 dA*dTdGdGdA*dC*dC*dAdGdTAb 1 Tb 1 224i C*b 1 ssAb 1 ssTb 1 ssGb 1 ssAb 1 ssdAssdTssdGssdGssdAssdCssdCssdAssdGssTb 1 ssAb 1 ssTb 1 224j C*b 4 Ab 4 Tb 4 dGdA*dA*dTdGdGdA*dCdCdAGb 4 Tb 4 Ab 4 Tb 4 224k C*b 6 sAb 6 sTb 6 sdGsdA*sdA*sdUsdGsdGsdA*sdC*sdC*sdAsdGsTb 6 sAb 6 sTb 6 224m C*b 7 sAb 7 sTb 7 sGb 7 sdAdAdTdGdGdAdC*dC*dAsGb 7 sTb 7 sAb 7 sTb 7 225a Tb 1 sC*b 1 sAb 1 sTb 1 sGb 1 sdAsdAsdTsdGsdGsdAsdCsdCsAb 1 sGb 1 sTb 1 sAb 1 sTb 1 225b Tb 7 sC*b 7 sAb 7 sTb 7 sGb 7 sdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsdTsdAsTb 7 225c Tb 1 sC*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdC*sdC*sdAsGb 1 sTb 1 sAb 1 sTb 1 225d Tb 1 sC*b 1 sAb 1 sdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 1 sTb 1 sAb 1 sTb 1 225e Tb 1 sC*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsTb 1 sAb 1 sTb 1 225f Tb 1 C*b 1 dA*dTdGdAdAdUdGdGdAdCdC*Ab 1 Gb 1 Tb 1 Ab 1 Tb 1 225g Tb 4 C*b 4 Ab 4 Tb 4 sdGsdAsdAsdTsdGsdGsdAsdCsdCsAb 4 Gb 4 Tb 4 Ab 4 Tb 4 225h Tb 1 ssC*b 1 ssAb 1 ssdTssdGssdA*ssdA*ssdTssdGssdGssdAssdCssdC*ssdA*ssdGssTb 1 ssAb 1 ssTb 1 225i Tb 2 C*b 2 Ab 2 dTdGdAdAdTdGdGdAdC*dC*Ab 2 Gb 2 Tb 2 Ab 2 Tb 2 226a Tb 1 sC*b 1 sAb 1 sTb 1 sGb 1 sdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 1 sTb 1 sAb 1 sTb 1 sTb 1 226b Tb 6 C*b 6 Ab 6 Tb 6 Gb 6 dAdAdTdGdGdAdCdCdAGb 6 Tb 6 Ab 6 Tb 6 Tb 6 226c Tb 1 sC*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsdTsAb 1 sTb 1 sTb 1 226d Tb 1 sdCsdAsdTsdGsdAsdA*sdUsdGsdGsdAsdCsdCsdAsGb 1 sTb 1 sAb 1 sTb 1 sTb 1 226e Tb 4 sC*b 4 sdAsdUsdGsdAsdAsdUsdGsdGsdAsdCsdC*sdAsdGsTb 4 sAb 4 sTb 4 sTb 4 226f Tb 2 ssC*b 2 ssAb 2 ssTb 2 ssGb 2 ssdAssdAssdTssdGssdGssdAssdCssdCssdAssdGssdTssdAssTb 2 ssTb 2 227a C*b 1 sTb 1 sC*b 1 sAb 1 sTb 1 sdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 1 sTb 1 sAb 1 sTb 1 sTb 1 227b C*b 2 sTb 2 sC*b 2 sdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 2 sTb 2 sAb 2 sTb 2 sTb 2 227c C*b 1 Tb 1 C*b 1 dAdTdGdAdAdTdGdGdAdCdC*dAdGTb 1 Ab 1 Tb 1 Tb 1 227d C*b 1 sdUsdCsdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsGb 1 sTb 1 sAb 1 sTb 1 sTb 1 227e C*b 4 sTb 4 sC*b 4 sAb 4 sdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsTb 4 sAb 4 sTb 4 sTb 4 228a Tb 1 sC*b 1 sTb 1 sC*b 1 sAb 1 sdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsTb 1 sAb 1 sTb 1 sTb 1 sC*b 1 228b Tb 1 C*b 1 Tb 1 C*b 1 Ab 1 dTdGdAdAdTdGdGdAdC*dC*dAdGTb 1 Ab 1 Tb 1 Tb 1 C*b 1 228c Tb 6 sC*b 6 sTb 6 sdCsdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsdTsAb 6 sTb 6 sTb 6 sC*b 6 229a Ab 1 sTb 1 sC*b 1 sTb 1 sC*b 1 sdAsdTsdGsdAsdAsdTsdGsdGsdAsdC*sdCsdAsdGsdTsAb 1 sTb 1 sTb 1 sC*b 1 sTb 1 229b Ab 1 Tb 1 C*b 1 Tb 1 C*b 1 AdTdGdAdAdTdGdGdAdCdCdAdGdTAb 1 Tb 1 Tb 1 C*b 1 Tb 1 230a Tb 1 sAb 1 sTb 1 sC*b 1 sTb 1 sdCsdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsdTsdAsTb 1 sTb 1 sC*b 1 sTb 1 sAb 1 230a Tb 1 sAb 1 sTb 1 sC*b 1 sTb 1 sdCsdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsdTsdAsTb 1 sTb 1 sC*b 1 sTb 1 sAb 1 230b Tb 1 Ab 1 Tb 1 C*b 1 Tb 1 dCdAdTdGdAdAdTdGdGdAdCdCdAdGdTdATb 1 Tb 1 C*b 1 Tb 1 Ab 1 231a Ab 1 sTb 1 sAb 1 sTb 1 sC*b 1 sdTsdCsdAsdTsdGsdAsdAsdTsdGsdGsdAsdCsdCsdAsdGsdTsdAsdTsTb 1 sC*b 1 sTb 1 sAb 1 sGb 1 231b Ab 1 Tb 1 Ab 1 Tb 1 C*b 1 dTdCdAdTdGdAdAdTdGdGdAdCdCdAdGdTdAdTTb 1 C*b 1 Tb 1 Ab 1 Gb 1 232a C*b1sGb1sdTsdC*sdAsdTsdAsdGsAb1sC*b1 232b C*b1Gb1dTdC*dAdTdAdGAb1C*b1 233a Tb1sC*b1sGb1sdTsdC*sdAsdTsdAsdGsAb1sC*b1sC*b1 233b Tb1C*b1Gb1dTdC*dAdTdAdGAb1C*b1C*b1 233c Tb1sC*b1sGb1sdTsdC*sdAsdTsdAsdGsdAsC*b1sC*b1 233d Tb1sdC*sdGsdTsdC*sdAsdTsdAsdGsdAsC*b1sC*b1 233e Tb1sC*b1sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b1 234a Tb1sC*b1sGb1sTb1sdCsdAsdTsdAsdGsdAsC*b1sC*b1sGb1 234b Tb1C*b1Gb1Tb1dCdAdUdAdGdAC*b1C*b1Gb1 234c Tb1sC*b1sGb1sTb1sdC*sdAsdTsdAsdGsdAsC*b1sC*b1sGb1 234d Tb1sC*b1sGb1sdTsdC*sdA*sdTsdA*sdGsdA*sdC*sC*b1sGb1 234e Tb1sC*b1sdGsdTsdC*sdAsdTsdA*sdGsdA*sdC*sdCsGb1 234f Tb1sdCsdGsdTsdC*sdA*sdTsdAsdGsAb1sC*b1sC*b1sGb1 142c C*b1sGb1sTb1sdCsdAsdTsdAsdGsdAsdCsdCsGb1sAb1 143i C*b1sTb1sC*b1sGb1sdTsdCsdAsdTsdAsdGsAb1sC*b1sC*b1sGb1 143j C*b4ssTb4ssC*b4ssdGssdTssdCssdAssdTssdAssdGssdA*ssC*b4ssC*b4ssGb4 143h C*b1sTb1sdCsdGsdTsdCsdAsdTsdAsdGsdAsC*b1sC*b1sGb1 143k C*b2ssTb2ssC*b2ssdGssdTssdCssdAssdTssdAssdGssdAssC*b2ssC*b2ssGb2 143m C*b1Tb1C*b1Gb1dUsdCsdAsdTsdAsdGsAb1C*b1C*b1Gb1 143n C*b1sTb1sC*b1sGb1sTb1sdCsdA*sdTsdA*sdGsdA*sC*b1sC*b1sGb1 143o C*b1sTb1sdCsdGsdUsdCsdAsdUsdAsGb1sAb1sC*b1sC*b1sGb1 143p C*b6sTb6sC*b6sGb6sdTsdCsdAsdTsdAsdGsdAsC*b6sC*b6sGb6 143q C*b7sTb7sC*b7sdGsdUsdCsdA*sdUsdA*sdGsdA*sC*b7sC*b7sGb7 143r C*b4sTb4sC*b4sGb4sdTsdC*sdA*sdTsdAsdGsdAsdC*sC*b4sGb4 143s C*b4Tb4C*b4Gb4dTdCdAdTdAdGdAdCC*b4Gb4 143t C*b1ssTb1ssC*b1ssdGssdTssdC*ssdAssdTssdAssdGssdAssC*b1ssC*b1ssGb1 143u C*b1Tb1sdCsdGsdUsdC*sdAsdUsdAsdGsdAsC*b1C*b1Gb1 143v C*b1Tb1sdC*sdGsdTsdC*sdA*sdTsdAsdGsdAsC*b1C*b1Gb1 143w C*b6sTb6sdC*dGdTdC*dAdTdAdGdAsC*b6sC*b6sGb6 143x C*b7sTb7sC*b7sGb7sdTsdC*sdAsdTsdAsdGsdAsC*b7sC*b7sGb7 143y C*b7sTb7sdC*sdGsdTsdCsdAsdUsdAsdGsAb7sC*b7sC*b7sGb7 143z C*b1sTb1sdC*sdGsdTsdC*sdAsdTsdAsdGsdAsC*b1sC*b1sGb1 143aa C*b1Tb1sdC*sdGsdTsdC*sdAsdTsdAsdGsdAsC*b1C*b1Gb1 143ab C*b1sTb1sdC*sdGsdTsdC*sdA*sdTsdAsdGsdA*sC*b1sC*b1sGb1 143ac C*b1sTb1sdC*sdGsdTsdCsdAsdTsdAsdGsdAsC*b1sC*b1sGb1 143ad C*b1Tb1dC*dGdTdCdAdTdAdGdAC*b1C*b1Gb1 143ae C*b1sTb1sdC*dGdTdC*dAdTdAdGdAsC*b1sC*b1sGb1 143af /5SpC3s/C*b1sTb1sdC*dGdTdC*dA*dTdAdGdA*sC*b1sC*b1sGb1 143ag C*b1sTb1sdC*dGdTdC*dA*dTdAdGdA*sC*b1sC*b1sGb1/3SpC3s/ 143ah /5SpC3s/C*b1sTb1sdC*dGdTdC*dA*dTdAdGdA*sC*b1sC*b1sGb1/3SpC3s/ 143ai C*b1sTb1sdC*sdGsdUsdC*sdA*sdUsdA*sdGsdA*sC*b1sC*b1sGb1 143aj C*b1sTb1sC*b1sdGsdTsdCsdAsdTsdAsdGsdAsC*b1sC*b1sGb1 145c Gb1sC*b1sTb1sdCsdGsdTsdCsdAsdTsdAsdGsAb1sC*b1sC*b1 235i C*b1sTb1sC*b1sGb1sdTdC*dAdTdAdGdAsC*b1sC*b1sGb1sAb1 235a C*b1ssTb1ssdCssdGssdTssdCssdAssdTssdAssdGssdAssdCssdCssdGssAb1 235b C*b1Tb1dCdGdTdCdAdTdAdGdAdCdCdGAb1 235c C*b1sTb1sdCsdGsdTsdCsdA*sdUsdAsdGsdAsdCsC*b1sGb1sAb1 235d C*b1Tb1sdCsdGsdTsdCsdAsdTsdAsdGsdAsC*b1C*b1Gb1Ab1 235e C*b4sTb4sC*b4sdGsdTsdCsdAsdTsdAsdGsdAsdCsdCsGb4sAb4 235f C*b6sTb6sC*b6sdGdTdCdA*dTdAdGdAdC*sC*b6sGb6sAb6 235g C*b1sTb1sC*b1sGb1sdTsdC*sdAsdTsdAsdGsdAsdC*sdC*sdGsAb1 235h C*b1ssTb1ssdCssdGssdUssdCssdAssdUssdAssdGssdAssdCssdCssGb1 ssAb1 144c Gb1sC*b1sTb1sdCsdGsdTsdCsdAsdTsdAsdGsdAsC*b1sC*b1sGb1 141c Gb1sC*b1sTb1sC*b1sdGsdTsdC*sdAsdTsdAsdGsdAsC*b1sC*b1sGb1sAb1 141d Gb1C*b1Tb1C*b1sdGsdTsdC*sdAsdTsdAsdGsdAsdCsC*b1Gb1Ab1 141e Gb4sC*b4sTb4sC*b4sdGsdTsdC*sdAsdTsdAsdGsdA*sdC*sdC*sGb4sAb4 141f Gb1sdC*sdTsdCsdGsdTsdC*sdA*sdTsdAsdGsdA*sdC*sdC*sdGsAb1 141g Gb2sC*b2sTb2sdCsdGsdUsdCsdAsdTsdA*sdGsdAsdCsC*b2sGb2sAb2 141h Gb4ssC*b4ssTb4ssdCssdGssdTssdCssdAssdTssdAssdGssdAssC*b4ssC*b4ssGb4ssAb4 141i Gb1C*b1dTdCdGdTdCdA*dTdA*dGdA*dCC*b1Gb1Ab1 141j Gb1sC*b1sTb1sdCsdGsdTsdCsdAsdTsdAsdGsdAsdCsC*b1sGb1sAb1 139c C*b1sGb1sTb1sdCsdAsdTsdAsdGsdAsdCsdCsdGsdAsGb1sC*b1sC*b1 237a Tb1sGb1sC*b1sTb1sC*b1sdGsdTsdC*sdAsdTsdAsdGsAb1sC*b1sC*b1sGb1sAb1 237b Tb2sGb2sC*b2sdTsdGsdTsdC*sdAsdTsdAsdGsAb2sC*b2sC*b2sGb2sAb2 237c Tb1sGb1sC*b1sTb1sdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b1sGb1sAb1 237d Tb1sdGsdCsdUsdC*sdGsdTsdC*sdAsdUsdAsdGsAb1sC*b1sC*b1sGb1sAb1 237e Tb1sGb1sC*b1sdTsdGsdTsdC*sdA*sdTsdA*sdGsAb1sC*b1sC*b1sGb1sAb1 237f Tb1Gb1dC*dTdGdTdC*dAdTdAdGdAC*b1C*b1Gb1Ab1 237g Tb1sdGsdC*sdTsdGsdTsdC*sdAsdTsdAsdGsdAsdC*sC*b1sGb1sAb1 237h Tb1Gb1C*b1Tb1C*b1dGdTdC*dA*dTdA*dGdA*dC*dC*Gb1Ab1 237i Tb1ssGb1ssC*b1ssTb1ssC*b1ssdGssdTssdCssdAssdTssdAssdGssdAssdCssC*b1ssGb1ssAb1 237j Tb4sGb4sC*b4sdTdGdTdCdA*dTdA*dGdA*sC*b4sC*b4sGb4sAb4 237k Tb6sGb6sC*b6sdUsdGsdUsdC*sdA*sdUsdA*sdGsdA*sdC*sC*b6sGb6sAb6 237m Tb7sGb7sC*b7sTb7sdC*dGdTdC*dAdTdAdGdAsC*b7sC*b7sGb7sAb7 238a Tb1sGb1sC*b1sTb1sC*b1sdGsdTsdC*sdAsdTsdAsdGsdAsC*b1sC*b1sGb1sAb1sGb1 238b Tb7sGb7sC*b7sTb7sC*b7sdGsdTsdC*sdAsdTsdAsdGsdAsdC*sdC*sdGsdAsGb7 238c Tb1sGb1sC*b1sTb1sdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b1sGb1sAb1sGb1 238d Tb1sGb1sdC*sdTsdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sdC*sGb1sAb1sGb1 238e Tb1sGb1sC*b1sTb1sdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sdC*sGb1sAb1sGb1 238f Tb1Gb1dC*dUdC*dGdTdC*dAdTdAdGdA*C*b1C*b1Gb1Ab1Gb1 238g Tb4Gb4C*b4Tb4sdCsdGsdTsdCsdAsdTsdAsdGsdAsC*b4C*b4Gb4Ab4Gb4 238h Tb1ssGb1ssC*b1ssdTssdC*ssdGssdTssdC*ssdAssdTssdA*ssdGssdAssdC*ssdC*ssGb1ssAb1ssGb1 238i Tb2Gb2C*b2dTdCdGdTdC*dAdTdAdGdAC*b2C*b2Gb2Ab2Gb2 239a Tb1sGb1sC*b1sTb1sC*b1sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b1sGb1sAb1sGb1sC*b1 239b Tb6Gb6C*b6Tb6C*b6dGdTdC*dAdTdAdGdAdC*C*b6Gb6Ab6Gb6C*b6 239c Tb1sGb1sC*b1sTb1sdC*sdGsdTsdCsdAsdTsdAsdGsdAsdCsdCsdGsAb1sGb1sC*b1 239d Tb1sdGsdCsdTsdCsdGsdTsdCsdAsdTsdAsdGsdA*sdC*sC*b1sGb1sAb1sGb1sC*b1 239e Tb4sGb4sdCsdUsdCsdGsdUsdCsdAsdTsdAsdGsdA*sdC*sdC*sGb4sAb4sGb4sC*b4 239f Tb2ssGb2ssC*b2ssTb2ssC*b2ssdGssdTssdCssdAssdTssdAssdGssdAssdCssdCssdGssdAssGb2ssC*b2 240a C*b1sTb1sGb1sC*b1sTb1sdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b1sGb1sAb1sGb1sC*b1 240b C*b2sTb2sGb2sdC*sdTsdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b2sGb2 sAb2sGb2sC*b2 240c C*b1Tb1Gb1dC*dTdC*dGdTdCdAdTdAdGdAdC*dC*Gb1Ab1Gb1C*b1 240d C*b1sdUsdGsdCsdUsdC*sdGsdTsdCsdAsdTsdAsdGsdAsdC*sC*b1sGb1sAb1sGb1sC*b1 240e C*b4sTb4sGb4sC*b4sdTsdCsdGsdTsdCsdAsdTsdAsdGsdAsdCsdCsGb4sAb4sGb4sC*b4 241a Gb1sC*b1sTb1sGb1sC*b1sdTsdC*sdGsdTsdCsdAsdTsdAsdGsdAsdCsdC*sGb1sAb1sGb1sC*b1sC*b1 241b Gb1C*b1Tb1Gb1C*b1dTdC*dGdTdC*dAdTdAdGdAdC*dC*Gb1Ab1Gb1C*b1C*b1 241c Gb1sC*b1sTb1sGb1sC*b1sdTsdCsdGsdTsdCsdAsdTsdAsdGsdAsdCsdCsGb1sAb1sGb1sC*b1sC*b1 242a C*b1sGb1sC*b1sTb1sGb1sdCsdTsdCsdGsdTsdCsdAsdTsdAsdGsdAsdCsdC*sdGsAb1sGb1sC*b1sC*b1sC*b1 242b C*b1Gb1C*b1Tb1Gb1dC*dTdCdGdTdCdAdTdAdGdAdCdC*dGAb1Gb1C*b1C*b1C*b1 243a C*b1sC*b1sGb1sC*b1sTb1sdGsdC*sdTsdCsdGsdTsdC*sdAsdTsdAsdGsdAsdCsdC*sdGsdAsGb1sC*b1sC*b1sC*b1sC*b1 243b C*b1C*b1Gb1C*b1Tb1dGdC*dTdCdGdTdC*dAdTdAdGdAdCdC*dGdAGb1C*b1C*b1C*b1C*b1 244a C*b1sC*b1sC*b1sGb1sC*b1sdTsdGsdCsdTsdCsdGsdTsdC*sdAsdTsdAsdGsdAsdC*sdCsdGsdAsdGsC*b1sC*b1sC*b1sC*b1sC*b1 244b C*b1C*b1C*b1Gb1C*b1dTdGdC*dTdCdGdTdC*dAdTdAdGdAdC*dCdGdAdGC*b1C*b1C*b1C*b1C*b1 245a Tb1sAb1sdC*sdGsdCsdGsdTsdC*sC*b1sAb1 245b Tb1Ab1dCdGdC*dGdTdCC*b1Ab1 246a Ab1sTb1sAb1sdC*sdGsdCsdGsdTsdCsC*b1sAb1sC*b1 246b Ab1Tb1Ab1dCdGdCdGdTdC*C*b1Ab1C*b1 246c Ab1sTb1sAb1sdCsdGsdCsdGsdTsdC*sdC*sAb1sC*b1 246d Ab1sTb1sdA*sdC*sdGsdCsdGsdTsdC*sdC*sdA*sC*b1 246e Ab1sdTsdA*sdC*sdGsdC*sdGsdTsdC*sdC*sAb1sC*b1 247a Gb1sAb1sTb1sAb1sdCsdGsdCsdGsdTsdCsC*b1sAb1sC*b1 247b Gb1Ab1Tb1Ab1dCdGdCdGdUdCC*b1Ab1C*b1 247c Gb1sAb1sTb1sAb1sdC*sdGsdCsdGsdTsdC*sC*b1sAb1sC*b1 247d Gb1sAb1sTb1sdA*sdCsdGsdCsdGsdTsdCsdC*sAb1sC*b1 247e Gb1sAb1sdTsdA*sdCsdGsdC*sdGsdTsdCsdC*sdA*sC*b1 247f Gb1sdA*sdTsdA*sdC*sdGsdCsdGsdTsC*b1sC*b1sAb1sC*b1 153f C*b1sGb1sAb1sdTsdAsdCsdGsdCsdGsdTsdCsC*b1sAb1 248a Gb1sAb1sTb1sAb1sdC*sdGsdC*sdGsdTsdC*sC*b1sAb1sC*b1sAb1 248b Gb1Ab1Tb1Ab1sdC*sdGsdCsdGsdTsdC*sdC*sAb1C*b1Ab1 248c Gb4sAb4sTb4sAb4sdC*sdGsdCsdGsdTsdC*sdC*sdA*sC*b4sAb4 248d Gb1sdA*sdTsdAsdCsdGsdCsdGsdTsdCsdC*sdA*sdCsAb1 248e Gb2sAb2sTb2sdA*sdCsdGsdCsdGsdUsdCsdCsAb2sC*b2sAb2 248f Gb4ssAb4ssdTssdAssdCssdGssdCssdGssdTssdCssdCssAb4ssC*b4ssAb4 248g Gb1Ab1dTdA*dCdGdCdGdTdCC*b1Ab1C*b1Ab1 152h C*b1sGb1sAb1sTb1sdAsdCsdGsdCsdGsdTsdCsdCsAb1sC*b1sAb1 152i C*b1Gb1Ab1Tb1sdAsdCsdGsdCsdGsdUsdCsdC*sAb1C*b1Ab1 152j C*b1Gb1Ab1Tb1sdA*sdCsdGsdCsdGsdUsdCsdCsAb1C*b1Ab1 152k C*b6sGb6sAb6sTb6sdAdC*dGdCdGdTdCdC*sAb6sC*b6sAb6 152m C*b1sGb1sAb1sTb1sdAsdCsdGsdCsdGsdTsdC*sdC*sAb1sC*b1sAb1 152n C*b1Gb1Ab1Tb1sdAsdC*sdGsdC*sdGsdTsdC*sdC*sAb1C*b1Ab1 152o C*b1sGb1sAb1sTb1sdA*sdCsdGsdCsdGsdTsdCsdC*sAb1sC*b1sAb1 152p C*b1sGb1sAb1sTb1sdAsdCsdGsdCsdGsdTsdCsdC*sAb1sC*b1sAb1 152q C*b1Gb1Ab1Tb1dAdCdGdC*dGdTdCdC*Ab1C*b1Ab1 152r C*b1sGb1sAb1sTb1sdAdC*dGdC*dGdTdC*dC*sAb1sC*b1sAb1 152s /5SpC3s/C*b1sGb1sAb1sTb1sdAsdC*sdGsdC*sdGsdTsdCsdCsAb1sC*b1sAb1 152t C*b1sGb1sAb1sTb1sdAsdC*sdGsdCsdGsdTsdCsdC*sAb1sC*b1sAb1/3SpC3s/ 152u /5SpC3s/C*b1sGb1sAb1sTb1sdAsdC*sdGsdC*sdGsdTsdCsdCsAb1sC*b1sAb1/3SpC3s/ 152v C*b1sGb1sAb1sTb1sdA*sdC*sdGsdC*sdGsdUsdC*sdC*sAb1sC*b1sAb1 152w C*b7sGb7sAb7sdTsdAsdCsdGsdC*sdGsdTsdCsC*b7sAb7sC*b7sAb7 152z C*b7sGb7sdAsdUsdAsdCsdGsdC*sdGsdUsdCsC*b7sAb7sC*b7sAb7 152aa C*b1ssGb1ssAb1ssdTssdAssdC*ssdGssdCssdGssdTssdCssdC*ssAb1ssC*b1ssAb1 152ab C*b4ssGb4ssAb4ssdTssdA*ssdCssdGssdCssdGssdTssdCssdCssdA*ssC*b4ssAb4 152ac C*b2ssGb2ssAb2ssTb2ssdAssdCssdGssdCssdGssdTssdCssdCssdAssdCssAb2 152ad C*b1Gb1Ab1Tb1dAdCdGdCdGdUdCC*b1Ab1C*b1Ab1 152ae C*b1sGb1sAb1sTb1sAb1sdCsdGsdCsdGsdUsdCsdCsAb1sC*b1sAb1 152af C*b1sGb1sdA*sdTsdA*sdCsdGsdCsdGsdTsC*b1sC*b1sAb1sC*b1sAb1 152ag C*b6sGb6sAb6sdTsdAsdCsdGsdCsdGsdTsdCsC*b6sAb6sC*b6sAb6 152ah C*b7sGb7sAb7sdUsdA*sdCsdGsdCsdGsdUsdCsdCsAb7sC*b7sAb7 152ai C*b4sGb4sAb4sTb4sdA*sdCsdGsdCsdGsdTsdC*sdC*sdA*sC*b4sAb4 152aj C*b4Gb4Ab4Tb4dAdCdGdCdGdTdCdCdAC*b4Ab4 152ak C*b1sGb1sAb1sdTsdAsdCsdGsdCsdGsdTsdCsdCsAb1sC*b1sAb1 249a C*b1sGb1sAb1sTb1sdAdCdGdCdGdTdCdC*sAb1sC*b1sAb1sGb1 249b C*b1ssGb1ssdAssdTssdAssdCssdGssdCssdGssdTssdCssdCssdAssdCssdAssGb1 249c C*b1Gb1dAdTdAdCdGdCdGdTdCdCdAdCdAGb1 249d C*b1sGb1sdAsdUsdAsdC*sdGsdCsdGsdUsdCsdC*sdAsC*b1sAb1sGb1 249e C*b1Gb1sdAsdTsdAsdC*sdGsdC*sdGsdTsdCsdC*sAb1C*b1Ab1Gb1 249f C*b4sGb4sAb4sdTsdAsdCsdGsdCsdGsdTsdCsdCsdAsdCsAb4sGb4 249g C*b6Gb6Ab6dTdA*dCdGdCdGdTdC*dCdA*C*b6Ab6Gb6 249h C*b1sGb1sAb1sTb1sdAsdC*sdGsdCsdGsdTsdCsdC*sdAsdC*sdAsGb1 249i C*b1ssGb1ssdAssdUssdAssdCssdGssdCssdGssdUssdCssdCssdAssdCssAb1ssGb1 250a Gb1sC*b1sGb1sAb1sTb1sdAsdCsdGsdC*sdGsdTsdCsC*b1sAb1sC*b1sAb1sGb1 250b Gb1sC*b1sGb1sAb1sdTsdAsdC*sdGsdC*sdGsdTsdC*sdC*sdAsC*b1sAb1sGb1 250c Gb1sdC*sdGsdAsdUsdAsdCsdGsdC*sdGsdUsdCsC*b1sAb1sC*b1sAb1sGb1 250d Gb1sC*b1sGb1sdA*sdTsdA*sdC*sdGsdC*sdGsdTsdC*sC*b1sAb1sC*b1sAb1sGb1 250e Gb1C*b1dGdAdTdAdCdGdC*dGdTdCdC*Ab1C*b1Ab1Gb1 250f Gb1sdC*sdGsdAsdTsdAsdCsdGsdC*sdGsdTsdCsdCsdAsC*b1sAb1sGb1 250g Gb2sC*b2sGb2sdAsdTsdAsdCsdGsdC*sdGsdTsdC*sC*b2sAb2sC*b2sAb2sGb2 250h Gb1C*b1Gb1Ab1Tb1dA*dCdGdC*dGdTdC*dCdA*dC*Ab1Gb1 250i Gb1ssC*b1ssGb1ssAb1ssTb1ssdAssdCssdGssdCssdGssdTssdCssdCssdAssC*b1ssAb1ssGb1 250j Gb4sC*b4sGb4sdA*sdTsdA*sdCsdGsdCsdGsdTsdCsdCsAb4sC*b4sAb4sGb4 250k Gb6sC*b6sGb6sdA*sdUsdAsdCsdGsdCsdGsdUsdC*sdCsdA*sC*b6sAb6sGb6 250m Gb7sC*b7sGb7sAb7sdTdAdCdGdCdGdTdC*dCsAb7sC*b7sAb7sGb7 251a Gb1sC*b1sGb1sAb1sTb1sdAsdCsdGsdCsdGsdTsdCsdC*sAb1sC*b1sAb1sGb1sGb1 251b Gb7sC*b7sGb7sAb7sTb7sdAsdC*sdGsdCsdGsdTsdCsdCsdAsdCsdAsdGsGb7 251c Gb1sC*b1sGb1sAb1sdTsdAsdC*sdGsdCsdGsdTsdCsdC*sdAsC*b1sAb1sGb1sGb1 251d Gb1sC*b1sGb1sdAsdTsdAsdC*sdGsdC*sdGsdTsdCsdC*sdAsC*b1sAb1sGb1sGb1 251e Gb1sC*b1sGb1sAb1sdTsdAsdC*sdGsdCsdGsdTsdCsdC*sdAsdC*sAb1sGb1sGb1 251f Gb1C*b1dGdAdUdA*dCdGdCdGdTdC*dC*Ab1C*b1Ab1Gb1Gb1 251g Gb4C*b4Gb4Ab4sdTsdAsdCsdGsdCsdGsdTsdCsdCsAb4C*b4Ab4Gb4Gb4 251h Gb1ssC*b1ssGb1ssdA*ssdTssdA*ssdCssdGssdCssdGssdTssdCssdCssdA*ssdC*ssAb1ssGb1ssGb1 251i Gb2C*b2Gb2dAdTdAdCdGdC*dGdTdCdC*Ab2C*b2Ab2Gb2Gb2 252a Gb1sC*b1sGb1sAb1sTb1sdAsdC*sdGsdCsdGsdTsdCsdCsdAsC*b1sAb1sGb1sGb1sAb1 252b Gb6C*b6Gb6Ab6Tb6dAdC*dGdCdGdTdCdC*dAC*b6Ab6Gb6Gb6Ab6 252c Gb1sC*b1sGb1sdAsdTsdAsdCsdGsdCsdGsdTsdCsdCsdAsdC*sAb1sGb1sGb1sAb1 252d Gb1sdC*sdGsdA*sdTsdA*sdC*sdGsdCsdGsdTsdCsdCsdA*sC*b1sAb1sGb1sGb1sAb1 252e Gb4sC*b4sdGsdAsdUsdAsdCsdGsdCsdGsdUsdCsdCsdAsdC*sAb4sGb4sGb4sAb4 252f Gb2ssC*b2ssGb2ssAb2ssTb2ssdAssdCssdGssdCssdGssdTssdCssdCssdAssdCssdAssdGssGb2ssAb2 253a Gb1sGb1sC*b1sGb1sAb1sdTsdAsdCsdGsdCsdGsdTsdC*sdC*sdAsC*b1sAb1sGb1sGb1sAb1 253b Gb2sGb2sC*b2sdGsdAsdTsdAsdC*sdGsdCsdGsdTsdC*sdC*sdAsC*b2sAb2sGb2sGb2sAb2 253c Gb1Gb1C*b1dGdAdTdAdCdGdCdGdTdCdCdAdC*Ab1Gb1Gb1Ab1 253d Gb1sdGsdCsdGsdAsdTsdAsdCsdGsdC*sdGsdUsdCsdCsdAsC*b1sAb1sGb1sGb1sAb1 253e Gb4sGb4sC*b4sGb4sdAsdTsdAsdCsdGsdCsdGsdTsdCsdCsdAsdCsAb4sGb4sGb4sAb4 254a Tb1sGb1sGb1sC*Gb1sdAsdTsdAsdCsdGsdCsdGsdTsdCsdCsdAsdC*sAb1sGb1sGb1sAb1sC*b1 254b Tb1Gb1Gb1C*b1Gb1dAdTdAdC*dGdCdGdTdCdC*dAdCAb1Gb1Gb1Ab1C*b1 254c Tb6sGb6sGb6sC*b6sdGsdAsdTsdAsdCsdGsdCsdGsdTsdCsdCsdAsdCsdAsdGsGb6sAb6sC*b6 255a C*b1sTb1sGb1sGb1sC*b1sdGsdAsdTsdAsdCsdGsdC*sdGsdTsdCsdC*sdAsdCsdAsGb1sGb1sAb1sC*b1sGb1 255b C*b1Tb1Gb1Gb1C*b1dGdAdTdAdCdGdC*dGdTdCdC*dAdC*dAGb1Gb1Ab1C*b1Gb1 256a Gb1sC*b1sTb1sGb1sGb1sdC*sdGsdAsdTsdAsdCsdGsdCsdGsdTsdCsdCsdAsdCsdAsdGsGb1sAb1sC*b1sGb1sAb1 256b Gb1C*b1Tb1Gb1Gb1dC*dGdAdTdAdCdGdCdGdTdCdCdAdC*dAdGGb1Ab1C*b1Gb1Ab1 257a Tb1sGb1sC*b1sTb1sGb1sdGsdCsdGsdAsdTsdAsdC*sdGsdC*sdGsdTsdCsdCsdAsdCsdAsdGsGb1sAb1sC*b1sGb1sAb1 257b Tb1Gb1C*b1Tb1Gb1dGdCdGdAdTdAdCdGdCdGdTdCdC*dAdC*dAdGGb1Ab1C*b1Gb1Ab1 258a Gb1sTb1sdGsdTsdTsdTsdA*sdGsGb1sGb1 258b Gb1sTb1sdGsdUsdTsdTsdA*sdGsGb1sGb1 259a Ab1sGb1sTb1sdGsdTsdTsdTsdA*sdGsGb1sGb1sAb1 259b Ab1Gb1Tb1dGdUdUdUdA*dGGb1Gb1Ab1 259c Ab1sGb1sTb1sdGsdTsdTsdTsdA*sdGsdGsGb1sAb1 259d Ab1sGb1sdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1 259e Ab1sdGsdTsdGsdTsdTsdTsdA*sdGsdGsGb1sAb1 260a Tb1sAb1sGb1sTb1sdGsdTsdTsdTsdAsdGsGb1sGb1sAb1 260b Tb1Ab1Gb1Tb1dGdUdUdUdAdGGb1Gb1Ab1 260c Tb1sAb1sGb1sTb1sdGsdTsdTsdTsdA*sdGsGb1sGb1sAb1 260d Tb1sAb1sGb1sdUsdGsdTsdTsdTsdA*sdGsdGsGb1sAb1 260e Tb1sAb1sdGsdUsdGsdUsdUsdUsdA*sdGsdGsdGsAb1 260f Tb1sdA*sdGsdTsdGsdTsdTsdUsdA*sGb1sGb1sGb1sAb1 261a Tb1sAb1sGb1sTb1sdGsdTsdTsdTsdA*sdGsGb1sGb1sAb1sGb1 261b Tb1Ab1Gb1Tb1sdGsdTsdTsdTsdA*sdGsdGGb1Ab1Gb1 261c Tb4sAb4sGb4sTb4sdGsdUsdTsdUsdA*sdGsdGsdGsAb4sGb4 261d Tb1sdA*sdGsdUsdGsdTsdTsdUsdA*sdGsdGsdGsdA*sGb1 261e Tb2sAb2sGb2sdUsdGsdUsdUsdTsdAsdGsdGsGb2sAb2sGb2 261f Tb4sAb4sdGsdTsdGsdTsdTsdTsdAsdGsdGsGb4sAb4sGb4 261g Tb1Ab1dGdTdGdTdTdTdA*dGGb1Gb1Ab1Gb1 262a Tb1sAb1sGb1sTb1sdGdTdTdTdA*dGdGsGb1sAb1sGb1sC*b1 262b Tb1ssAb1ssdGssdTssdGssdTssdTssdTssdAssdGssdGssdGssdAssdGssC*b1 262c Tb1sAb1sdGsdUsdGsdUsdUsdUsdA*sdGsdGsdGsAb1sGb1sC*b1 262d Tb1dAdGdTdGdTdTdTdAdGdGdGdAdGC*b1 262e Tb1Ab1sdGsdUsdGsdUsdTsdUsdAsdGsdGsGb1Ab1Gb1C*b1 262f Tb4sAb4sGb4sdTsdGsdTsdTsdTsdAsdGsdGsdsdGsdAsGb4sC*b4 262g Tb6Ab6Gb6dUdGdTdTdUdAdGdGdGAb6Gb6C*b6 262h Tb1sAb1sGb1sTb1sdGsdTsdTsdTsdAsdGsdGsdGsdAsdGsC*b1 262i Tb1ssAb1ssdGssdTssdGssdUssdUssdUssdAssdGssdGssdGssdAssGb1ssC*b1 209s Gb1Tb1dAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1Gb1C*b1 209t Gb1sTb1sdA*sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1 209u Gb1Tb1dAdGdTdGdTdTdTdAdGdGdGAb1Gb1C*b1 209v /5SpC3s/Gb1sTb1sdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1sGb1sC*b1 209w Gb1sTb1sdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1sGb1sC*b1/s3SpC3/ 209x /5SpC3s/Gb1sTb1sdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1sGb1sC*b1/3SpC3s/ 209y Gb1sTb1sdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1sGb1sC*b1 209aa Gb1Tb1dA*sdGsdUsdGsdUsdUsdUsdAsdGsdGsdGsAb1Gb1C*b1 209ab Gb1Tb1dA*sdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1Gb1C*b1 209ac Gb6sTb6sdA*dGdTdGdTdTdTdA*dGdGdGAb6sGb6sC*b6 209ad Gb1sTb1sdA*sdGsdUsdGsdUsdUsdUsdA*sdGsdGsdGsAb1sGb1sC*b1 209ae Gb1sTb1sdA*sdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1sGb1sC*b1 209af Gb1sTb1sdAsdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1 209ag Gb1Tb1dA*dGdTdGdTdTdTdA*dGdGdGAb1Gb1C*b1 209ah Gb1Tb1dAdGdTdGdTdTdTdA*dGdGdGAb1Gb1C*b1 209ai Gb6sTb6sdA*dGdTdGdTdTdTdAdGdGdGAb6sGb6sC*b6 209aj Gb1sTb1sdA*sdGsdUsdGsdTsdTsdUsdA*sdGsdGsdGsAb1sGb1sC*b1 209ak Gb7sTb7sAb7sGb7sdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb7sGb7sC*b7 209am Gb7sTb7sdAsdGsdTsdGsdTsdTsdUsdA*sdGsdGsGb7sAb7sGb7sC*b7 209an Gb1ssTb1ssAb1ssdGssdTssdGssdTssdTssdTssdA*ssdGssdGssdGssAb1ssGb1ssC*b1 209ao Gb4ssTb4ssAb4ssdGssdTssdGssdTssdTssdTssdAssdGssdGssdGssdA*ssGb4ssC*b4 209ap Gb2ssTb2ssAb2ssGb2ssdTssdGssdTssdTssdTssdAssdGssdGssdGssdAssdGssC*b2 209aq Gb1Tb1Ab1Gb1dUdGdUdUdUdAdGdGGb1Ab1Gb1C*b1 209ar Gb1sTb1sAb1sGb1sTb1sdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1 209as Gb1sTb1sdAsdGsdTsdGsdTsdTsdUsdAsdGsGb1sGb1sAb1sGb1sC*b1 209at Gb6sTb6sAb6sGb6sdTsdGsdTsdTsdTsdAsdGsdGsdGsAb6sGb6sC*b6 209au Gb7sTb7sAb7sdGsdUsdGsdTsdTsdTsdA*sdGsdGsdGsAb7sGb7sC*b7 209av Gb4sTb4sAb4sGb4sdUsdGsdTsdUsdTsdA*sdGsdGsdGsdA*sGb4sC*b4 209aw Gb4Tb4Ab4Gb4dTdGdTdTdTdAdGdGdGdAGb4C*b4 209ax Gb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsAb1sGb1sC*b1 209az Gb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdAsdGsdGsGb1sAb1sGb1sC*b1 209ba Gb1sTb1sAb1sGb1sdTsdGsdTsdTsdTsdAsdGsdGsGb1sAb1sGb1sC*b1 209bb Gb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsGb1sC*b1 263a Gb1sTb1sAb1sGb1sTb1sdGsdTsdTsdTsdA*sdGsdGsGb1sAb1sGb1sC*b1sC*b1 263b Gb2sTb2sAb2sdGsdTsdGsdTsdTsdTsdA*sdGsdGsGb2sAb2sGb2sC*b2sC*b2 263c Gb1sTb1sAb1sGb1sdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1 263d Gb1sdUsdA*sdGsdUsdGsdUsdTsdTsdA*sdGsdGsGb1sAb1sGb1sC*b1sC*b1 263e Gb1sTb1sAb1sdGsdTsdGsdUsdTsdTsdA*sdGsdGsGb1sAb1sGb1sC*b1sC*b1 263f Gb1Tb1dA*dGdTdGdTdTdTdA*dGdGdGAb1Gb1C*b1C*b1 263g Gb1sdTsdA*sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsdA*sGb1sC*b1sC*b1 263h Gb1Tb1Ab1Gb1Tb1dGdTdUdTdAdGdGdGdA*dGC*b1C*b1 263i Gb1ssTb1ssAb1ssGb1ssTb1ssdGssdTssdTssdTssdAssdGssdGssdGssdAssGb1ssC*b1ssC*b1 263j Gb4Tb4dA*dGdTdGdTdTdTdAdGdGdGdA*Gb4C*b4C*b4 263k Gb6sTb6sAb6sdGsdTsdGsdUsdUsdTsdAsdGsdGsdGsdA*sGb6sC*b6sC*b6 263m Gb7sTb7sAb7sGb7sdTdGdTdTdTdA*dGdGdGsAb7sGb7sC*b7sC*b7 264a Gb1sGb1sTb1sAb1sGb1sdTsdGsdTsdTsdTsdA*sdGsdGsGb1sAb1sGb1sC*b1sC*b1 264b Gb7sGb7sTb7sAb7sGb7sdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsdGsdC*sC*b7 264c Gb1sGb1sTb1sAb1sGb1sdTsdGsdTsdTsdTsdAsdGsdGsdGsdA*sdGsdC*sC*b1 264d Gb1sGb1sTb1sAb1sGb1sdUsdGsdTsdTsdTsdAsdGsdGsdGsdA*sdGsdC*sC*b1 264e Gb1sGb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1 264f Gb1sGb1sTb1sdA*sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1 264g Gb1sGb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsdA*sGb1sC*b1sC*b1 264h Gb1Gb1dUdA*dGdTdGdTdTdTdAdGdGGb1Ab1Gb1C*b1C*b1 264i Gb4Gb4Tb4Ab4dGsdTsdGsdTsdTsdTsdAsdGsdGsGb4Ab4Gb4C*b4C*b4 264j Gb1ssGb1ssTb1ssdA*ssdGssdTssdGssdUssdTssdTssdA*ssdGssdGssdGssdA*ssGb1ssC*b1ssC*b1 264k Gb2Gb2Tb2dA*dGdTdGdTdTdTdAdGdGGb2Ab2Gb2C*b2C*b2 265a Gb1sGb1sTb1sAb1sGb1sdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1sGb1 265b Gb6Gb6Tb6Ab6Gb6dTdGdTdTdTdA*dGdGdGAb6Gb6C*b6C*b6Gb6 265c Gb1sGb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsdA*sdGsC*b1sC*b1sGb1 265d Gb1sdGsdTsdA*sdGsdUsdGsdTsdUsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1sGb1 265e Gb4sGb4sdUsdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdA*sGb4sC*b4sC*b4sGb4 265f Gb2ssGb2ssTb2ssAb2ssGb2ssdTssdGssdTssdTssdTssdAssdGssdGssdGssdAssdGssdCssC*b2ssGb2 266a Tb1sGb1sGb1sTb1sAb1sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1sGb1 266b Tb2sGb2sGb2sdTsdA*sdGsdTsdGsdTsdTsdTsdA*sdGsdGsdGsAb2sGb2sC*b2sC*b2sGb2 266c Gb1Gb1Tb1dA*dGdTdGdTdTdTdA*dGdGdGdA*Gb1C*b1C*b1Gb1 266d Tb1sdGsdGsdUsdA*sdGsdTsdGsdTsdUsdTsdA*sdGsdGsdGsAb1sGb1sC*b1sC*b1sGb1 266e Tb4sGb4sGb4sTb4sdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsGb4sC*b4sC*b4sGb4 267a Tb1sTb1sGb1sGb1sTb1sdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdA*sGb1sC*b1sC*b1sGb1sTb1 267b Tb1Tb1Gb1Gb1Tb1dA*dGdTdGdTdTdTdAdGdGdGdA*Gb1C*b1C*b1Gb1Tb1 267c Tb6sTb6sGb6sdGsdTsdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsGb6sC*b6sC*b6sGb6sTb6 268a Tb1sTb1sTb1sGb1sGb1sdTsdA*sdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsdGC*b1sC*b1sGb1sTb1sC*b1 268b Tb1Tb1Tb1Gb1Gb1dTdA*dGdTdGdTdTdTdAdGdGdGdA*dGC*b1C*b1Gb1Tb1C*b1 269a Ab1sTb1sTb1sTb1sGb1sdGsdTsdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsdGsdC*sC*b1sGb1sTb1sC*b1sTb1 269b Ab1Tb1Tb1Tb1Gb1dGdTdAdGdTdGdTdTdTdAdGdGdGdAdGdC*C*b1Gb1Tb1C*b1Tb1 270a Tb1sAb1sTb1sTb1sTb1sdGsdGsdTsdAsdGsdTsdGsdTsdTsdTsdAsdGsdGsdGsdAsdGsdC*sdCsGb1sTb1sC*b1sTb1sTb1 270b Tb1Ab1Tb1Tb1Tb1dGdGdTdAdGdTdGdTdTdTdAdGdGdGdAdGdC*dC*Gb1Tb1C*b1Tb1Tb1 271a Ab1sTb1sdTsdTsdGsdGsdTsdA*sGb1sTb1 271b Ab1Tb1dTdTdGdGdTdA*Gb1Tb1 272a Tb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sGb1sTb1sGb1 272b Tb1Ab1Tb1dTdTdGdGdTdA*Gb1Tb1Gb1 272c Tb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sdGsTb1sGb1 272d Tb1sAb1sdTsdTsdTsdGsdGsdTsdA*sdGsdUsGb1 272e Tb1sdAsdTsdUsdTsdGsdGsdUsdA*sdGsTb1sGb1 273a Tb1sAb1sTb1sdTsdTsdGsdGsdTsdAsGb1sTb1sGb1sTb1 273b Tb1Ab1Tb1dUdUdGdGdUdAGb1Tb1Gb1Tb1 273c Tb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sGb1sTb1sGb1sTb1 273d Tb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sdGsdUsGb1sTb1 273e Tb1sAb1sdUsdUsdUsdGsdGsdUsdA*sdGsdUsdGsTb1 273f Tb1sdA*sdTsdTsdUsdGsdGsdTsdA*sGb1sTb1sGb1sTb1 274a C*b1Tb1Ab1sdUsdTsdTsdGsdGsdTsdA*sGb1Tb1Gb1Tb1 274b C*b4sTb4sAb4sTb4sdTsdTsdGsdGsdTsdA*sdGsdUsGb4sTb4 274c C*b1sdUsdA*sdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb1 274d C*b2sTb2sAb2sdTsdTsdUsdGsdGsdTsdA*sdGsTb2sGb2sTb2 274e C*b4ssTb4ssdAssdTssdTssdTssdGssdGssdTssdAssdGssTb4ssGb4ssTb4 274f C*b1Tb1Ab1dTdTdTdGdGdTdA*Gb1Tb1Gb1Tb1 274g C*b1sTb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sGb1sTb1sGb1sTb1 275a C*b1sTb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sdGsdTsdGsdTsTb1 275b C*b1sTb1sdA*sdUsdTsdUsdGsdGsdTsdAsdGsdUsGb1sTb1sTb1 275c C*b4sTb4sAb4sdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb4sTb4 275d C*b1ssTb1ssdAssdTssdTssdTssdGssdGssdTssdAssdGssdTssdGssdTssTb1 275e C*b1ssTb1ssdAssdUssdTssdTssdGssdGssdTssdAssdGssdUssdGssTb1ssTb1 275f C*b1sTb1sAb1sTb1sdTdTdGdGdTdA*dGsTb1sGb1sTb1sTb1 275g C*b1Tb1sdAsdTsdTsdTsdGsdGsdTsdA*sdGsTb1Gb1Tb1Tb1 275h C*b6Tb6Ab6dUdTdTdGdGdTdA*dGdUGb6Tb6Tb6 275i C*b1dTdAdTdTdTdGdGdTdAdGdTdGdTTb1 210o Gb1C*b1Tb1Ab1dTsdTsdTsdGsdGsdTsdAsdGsdTsGb1Tb1Tb1 210p Gb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1 210q Gb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdAsdGsdTsGb1sTb1sTb1 210r Gb1C*b1Tb1Ab1dTdTdTdGdGdTdA*dGdTGb1Tb1Tb1 210s Gb1sC*b1sTb1sAb1sdUsdUsdTdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1 210t Gb1sC*b1sTb1sAb1sdUsdTsdTsdGsdGsdTsdAsdGsdUsGb1sTb1sTb1 210u Gb1sC*b1sTb1sAb1sdUsdUsdUsdGsdGsdUsdA*sdGsdUsGb1sTb1sTb1 210v /5SpC3s/Gb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdAsdGsdTsGb1sTb1sTb1 210w Gb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdAsdGsdTsGb1sTb1sTb1/3SpC3s/ 210x /5SpC3s/Gb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdAsdGsdTsGb1sTb1sTb1/3SpC3s/ 210y Gb1C*b1Tb1Ab1sdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1Tb1Tb1 210z Gb1C*b1Tb1Ab1sdUsdTsdTsdGsdGsdUsdA*sdGsdTsGb1Tb1Tb1 210aa Gb1sC*b1sTb1sAb1sdTdTdTdGdGdTdA*dGdTsGb1sTb1sTb1 210ab Gb6sC*b6sTb6sAb6sdTdTdTdGdGdTdA*dGdTsGb6sTb6sTb6 210ac Gb6sC*b6sTb6sdAsdTsdTsdTsdGsdGsdTsdAsdGsTb6sGb6sTb6sTb6 210ad Gb7sC*b7sTb7sdA*sdTsdTsdTsdGsdGsdTsdA*sdGsTb7sGb7sTb7sTb7 210ae Gb7sC*b7sdUsdAsdTsdTsdUsdGsdGsdUsdA*sdGsTb7sGb7sTb7sTb7 210af Gb1ssC*b1ssTb1ssdAssdTssdTssdTssdGssdGssdTssdA*ssdGssdTssGb1ssTb1ssTb1 210ag Gb4ssC*b4ssTb4ssdA*ssdTssdTssdTssdGssdGssdTssdAssdGssdTssdGssTb4ssTb4 210ah Gb2ssC*b2ssTb2ssAb2ssdTssdTssdTssdGssdGssdTssdAssdGssdTssdGssdTssTb2 210ai Gb1C*b1Tb1Ab1dUsdTsdTsdGsdGsdTsdAsdGsTb1Gb1Tb1Tb1 210aj Gb4C*b4Tb4Ab4dTsdTsdTsdGsdGsdTsdAsdGsdTdGTb4Tb4 210ak Gb1sC*b1sTb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1 210am Gb4sC*b4sTb4sAb4sdTsdTsdUsdGsdGsdTsdA*sdGsdTsdGsTb4sTb4 210an Gb7sC*b7sTb7sdA*sdTsdTsdUsdGsdGsdTsdA*sdGsdTsGb7sTb7sTb7 210ao Gb1sC*b1sdUsdAsdUsdUsdTsdGsdGsdUsdAsGb1sTb1sGb1sTb1sTb1 210ap Gb1sC*b1sTb1sdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsGb1sTb1sTb1 210aq Gb1sC*b1sTb1sdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb1sTb1 276a Gb1sC*b1sTb1sAb1sTb1sdTsdTsdGsdGsdTsdA*sdGsTb1sGb1sTb1sTb1sTb1 276b Gb2sC*b2sTb2sdAsdTsdTsdTsdGsdGsdTsdA*sdGsTb2sGb2sTb2sTb2sTb2 276c Gb1sC*b1sTb1sdAsdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1 276d Gb2sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsTb2sGb2sTb2sTb2sTb2 276e Gb6sC*b6sTb6sdA*sdUsdUsdUsdGsdGsdUsdA*sdGsdUsdGsTb6sTb6sTb6 276f Gb1sdC*sdTsdA*sdUsdUsdUsdGsdGsdUsdAsdGsdUsdGsTb1sTb1sTb1 276g Gb1C*b1dTdA*dTdTdTdGdGdTdA*dGdTGb1Tb1Tb1Tb1 276h Gb4C*b4Tb4Ab4dTdTdTdGdGdTdA*dGdTdGTb4Tb4Tb4 276i Gb1C*b1Tb1Ab1Tb1dUdTdGdGdTdA*dGdTdGdUTb1Tb1 276j Gb1ssC*b1ssTb1ssAb1ssTb1ssdTssdTssdGssdGssdTssdAssdGssdTssdGssTb1ssTb1ssTb1 276k Gb7sC*b7sTb7sAb7sdTdTdTdGdGdTdA*dGdTsGb7sTb7sTb7sTb7 277a Ab1sGb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdA*sdGsTb1sGb1sTb1sTb1sTb1 277b Ab7sGb7sC*b7sTb7sAb7sdTsdTsdTsdGsdGsdTsdA*sdGsdTsdGsdTsdTsTb7 277c Ab1sGb1sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsTb1sGb1sTb1sTb1sTb1 277d Ab1sGb1sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdA*sdGsTb1sGb1sTb1sTb1sTb1 277e Ab1Gb1dC*dTdAdUdTdTdGdGdTdA*dGTb1Gb1Tb1Tb1Tb1 277f Ab2Gb2C*b2dTdAdTdTdTdGdGdTdA*dGTb2Gb2Tb2Tb2Tb2 277g Ab1sGb1sC*b1sTb1sdA*sdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1 277h Ab1sGb1sC*b1sTb1sdA*sdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb1sTb1sTb1 277i Ab1sGb1sC*b1sdTsdA*sdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1 277j Ab4Gb4C*b4Tb4sdAsdTsdTsdTsdGsdGsdTsdAsdGsTb4Gb4Tb4Tb4Tb4 277k Ab1ssGb1ssC*b1ssdTssdA*ssdTssdTssdTssdGssdGssdTssdA*ssdGssdUssdGssTb1ssTb1ssTb1 278a Ab1sGb1sC*b1sTb1sAb1sdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1sAb1 278b Ab2ssGb2ssC*b2ssTb2ssAb2ssdTssdTssdTssdGssdGssdTssdAssdGssdTssdGssdTssdTssTb2ssAb2 278c Ab1sdGsdC*sdTsdAsdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1sAb1 278d Ab1sdGsdC*sdTsdAsdTsdTsdTsdGsdGsdUsdA*sdGsdUsGb1sTb1sTb1sTb1sAb1 278e Ab1sGb1sC*b1sdTsdAsdTsdTsdTsdGsdGsdTsdA*sdGsdTsdGsTb1sTb1sTb1sAb1 278f Ab4sGb4sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb4sTb4sTb4sAb4 278g Ab6Gb6C*b6Tb6Ab6dTdTdTdGdGdTdA*dGdTGb6Tb6Tb6Tb6Ab6 279a Gb1sAb1sGb1sC*b1sTb1sdAsdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1sAb1 279b Gb2sAb2sGb2sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsGb2sTb2sTb2sTb2sAb2 279c Gb1sdAsdGsdC*sdUsdAsdTsdTsdTsdGsdGsdTsdA*sdGsdTsGb1sTb1sTb1sTb1sAb1 279d Gb4sAb4sGb4sC*b4sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb4sTb4sTb4sAb4 279e Gb1Ab1Gb1dC*dTdAdTdTdTdGdGdTdAdGdTdGTb1Tb1Tb1Ab1 280a Ab1sGb1sAb1sGb1sC*b1sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb1sTb1sTb1sAb1sGb1 280b Ab1Gb1Ab1Gb1C*b1dTdAdTdTdTdGdGdTdAdGdTdGTb1Tb1Tb1Ab1Gb1 280c Ab1sGb1sAb1sGb1sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsTb1sTb1sTb1sAb1sGb1 280d Ab6sGb6sAb6sGb6sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdA*sdGsdTsdGsdTsdTsTb6sAb6sGb6 281a Ab1sAb1sGb1sAb1sGb1sdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsdTsTb1sTb1sAb1sGb1sGb1 281b Ab1Ab1Gb1Ab1Gb1dC*dTdAdTdTdTdGdGdTdAdGdTdGdTTb1Tb1Ab1Gb1Gb1 282a Gb1sAb1sAb1sGb1sAb1sdGsdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsdTsdTsTb1sAb1sGb1sGb1sGb1 282b Gb1Ab1Ab1Gb1Ab1dGdC*dTdAdTdTdTdGdGdTdAdGdTdGdTdTTb1Ab1Gb1Gb1Gb1 283a Ab1sGb1sAb1sAb1sGb1sdAsdGsdC*sdTsdAsdTsdTsdTsdGsdGsdTsdAsdGsdTsdGsdTsdTsdTsAb1sGb1sGb1sGb1sAb1 283b Ab1Gb1Ab1Ab1Gb1dAdGdC*dTdAdTdTdTdGdGdTdAdGdTdGdTdTdTAb1Gb1Gb1Gb1Ab1 284a C*b1sAb1sdTsdTsdAsdAsdTsdA*sAb1sAb1 284b C*b1Ab1dTdTdA*dAdTdA*Ab1Ab1 285a Gb1sC*b1sAb1sdTsdTsdA*sdA*sdTsdAsAb1sAb1sGb1 285b Gb1sC*b1sAb1sdTsdTsdA*sdA*sdTsdAsdA*sAb1sGb1 285c Gb1sC*b1sdAsdTsdTsdA*sdA*sdUsdAsdA*sdA*sGb1 285d Gb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsAb1sGb1 285e Gb1sdC*sdAsdTsdTsdAsdAsdTsdAsdA*sAb1sGb1 285f Gb1C*b1Ab1dTdTdA*dA*dTdAAb1Ab1Gb1 286a Gb1sC*b1sAb1sTb1sdTsdAsdAsdTsdAsdAsAb1sGb1sTb1 286b Gb1sC*b1sAb1sTb1sdTsdA*sdA*sdTsdAsdAsAb1sGb1sTb1 286c Gb1sC*b1sAb1sdUsdTsdAsdAsdTsdAsdAsdA*sGb1sTb1 286d Gb1sC*b1sdAsdTsdTsdAsdA*sdUsdAsdAsdAsdGsTb1 286e Gb1sdC*sdAsdTsdTsdAsdAsdTsdAsAb1sAb1sGb1sTb1 286f Gb1sdC*sdAsdTsdTsdAsdAsdTsdA*sAb1sAb1sGb1sTb1 286g Gb1C*b1Ab1Tb1dUdAdAdUdAdAAb1Gb1Tb1 287a Gb1sGb1sC*b1sAb1sdTsdTsdA*sdAsdTsdAsAb1sAb1sGb1sTb1 287b Gb4sGb4sC*b4sAb4sdTsdTsdA*sdAsdUsdAsdAsdA*sGb4sTb4 287c Gb1sdGsdCsdAsdUsdUsdAsdAsdTsdA*sdA*sdA*sdGsTb1 287d Gb2sGb2sC*b2sdA*sdUsdTsdA*sdAsdTsdAsdA*sAb2sGb2sTb2 287e Gb1Gb1C*b1Ab1sdTsdTsdAsdAsdTsdA*sdA*sAb1Gb1Tb1 287f Gb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsAb1sAb1sGb1sTb1 287g Gb1sGb1sdC*sdA*sdTsdTsdA*sdA*sdTsdA*sAb1sAb1sGb1sTb1 287h Gb1Gb1dC*dAdTdTdAdAdTdAAb1Ab1Gb1Tb1 287i Gb4ssGb4ssdCssdAssdTssdTssdAssdAssdTssdAssAb4ssAb4ssGb4ssTb4 287j Gb4ssGb4ssdC*ssdAssdTssdTssdAssdAssdTssdAssAb4ssAb4ssGb4ssTb4 288a Gb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1 288b Gb1sGb1sC*b1sAb1sdTsdTsdA*sdA*sdTsdAsdAsdAsdGsdTsGb1 288c Gb4sGb4sC*b4sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsTb4sGb4 288d Gb1sGb1sC*b1sAb1sdTdTdAdAdTdAdAsAb1sGb1sTb1sGb1 288e Gb1Gb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsAb1Gb1Tb1Gb1 288f Gb1ssGb1ssdCssdAssdUssdUssdAssdAssdUssdAssdAssdAssdGssTb1ssGb1 288g Gb1ssGb1ssdCssdAssdTssdTssdAssdAssdTssdAssdAssdAssdGssdTssGb1 288h Gb6Gb6C*b6dA*dTdTdAdAdUdA*dA*dAGb6Tb6Gb6 288i Gb1Gb1C*b1dAdTdTdAdAdUdAdAdAGb1Tb1Gb1 289a Ab1sGb1sGb1sC*b1sAb1sdTsdTsdA*sdA*sdTsdA*sAb1sAb1sGb1sTb1sGb1 289b Ab1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsAb1sAb1sGb1sTb1sGb1 289c Ab1sGb1sGb1sdC*sdA*sdTsdTsdA*sdA*sdTsdA*sAb1sAb1sGb1sTb1sGb1 289d Ab2sGb2sGb2sdC*sdAsdTsdTsdAsdAsdTsdAsAb2sAb2sGb2sTb2sGb2 289e Ab1sdGsdGsdC*sdAsdTsdTsdAsdAsdTsdAsAb1sAb1sGb1sTb1sGb1 289f Ab1sdGsdGsdC*sdAsdTsdUsdAsdAsdUsdAsAb1sAb1sGb1sTb1sGb1 289g Ab1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsAb1sGb1sTb1sGb1 289h Ab1sGb1sGb1sC*b1sdA*sdTsdTsdA*sdA*sdTsdA*sdAsdAsGb1sTb1sGb1 289i Ab6sGb6sGb6sdC*sdA*sdUsdTsdAsdAsdTsdAsdAsdAsGb6sTb6sGb6 289j Ab1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1 289k Ab1sdGsdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1 289m Ab1Gb1Gb1C*b1Ab1dUdTdA*dA*dTdAdAdAdGTb1Gb1 289n Ab1Gb1dGdC*dAdTdTdAdAdTdAdAAb1Gb1Tb1Gb1 289o Ab4Gb4Gb4dCdA*dTdTdAdAdTdAdA*Ab4Gb4Tb4Gb4 289p Ab1ssGb1ssGb1ssC*b1ssAb1ssdTssdTssdAssdAssdTssdAssdAssdAssGb1ssTb1ssGb1 289q Ab7sGb7sGb7sC*b7sdA*dTdTdAdAdTdAdA*sAb7sGb7sTb7sGb7 213j C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1 213k C*b1sAb1sGb1sdGsdCsdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1 213m C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdA*sdA*sGb1sTb1sGb1 213n C*b1Ab1Gb1dGdC*dAdTdTdAdAdTdAdAdAGb1Tb1Gb1 213o /5SpC3s/C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1 213p C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1/3SpC3s/ 213q /5SpC3s/C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1/3SpC3s/ 213r C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdUsdAsdAsdA*sGb1sTb1sGb1 213s C*b6sAb6sGb6sdGdC*dAdTdTdAdAdTdAdAdAsGb6sTb6sGb6 213t C*b1sAb1sGb1sdGdC*dAdTdTdAdAdTdAdAdAsGb1sTb1sGb1 213u C*b1Ab1Gb1sdGsdC*sdAsdUsdUsdAsdAsdUsdAsdAsdAsGb1Tb1Gb1 213v C*b1Ab1Gb1sdGsdC*sdAsdTsdTsdAsdA*sdTsdAsdAsdA*sGb1Tb1Gb1 213w C*b1Ab1Gb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1Tb1Gb1 213x C*b7sAb7sGb7sGb7sdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb7sTb7sGb7 213y C*b6sAb6sGb6sGb6sdCsdAsdTsdTsdAsdAsdTsdAsdAsdAsGb6sTb6sGb6 213z C*b7sAb7sGb7sdGsdCsdA*sdUsdTsdAsdAsdTsdAsdAsAb7sGb7sTb7sGb7 213aa C*b4sAb4sGb4sGb4sdC*sdA*sdTsdTsdAsdAsdTsdAsdA*sdAsdGsTb4sGb4 213ab C*b1sAb1sGb1sGb1sC*b1sdA*sdTsdTsdA*sdA*sdTsdAsdA*sdA*sGb1sTb1sGb1 213ac C*b1sAb1sGb1sdGsdCsdAsdTsdTsdA*sdA*sdTsdAsAb1sAb1sGb1sTb1sGb1 213ad C*b1sAb1sdGsdGsdC*sdAsdTsdTsdAsdAsdUsdAsdAsAb1sGb1sTb1sGb1 213ae C*b1ssAb1ssGb1ssdGssdC*ssdAssdTssdTssdAssdAssdTssdAssdAssAb1ssGb1ssTb1ssGb1 213af C*b4ssAb4ssGb4ssdGssdCssdAssdTssdTssdA*ssdAssdTssdAssdAssdAssdGssTb4ssGb4 213ag C*b2ssAb2ssGb2ssGb2ssdCssdAssdTssdTssdAssdAssdTssdAssdAssdAssdGssdTssGb2 213ah C*b1Ab1Gb1Gb1dCdAdTdTdAdAdUdAdAAb1Gb1Tb1Gb1 213ai C*b4Ab4Gb4Gb4dCdAdTdTdAdAdTdAdAdAdGTb4Gb4 213aj C*b1Ab1Gb1dGdCdAdTdTdAdAdUdAdAdAGb1Tb1Gb1 213ak C*b1sAb1sGb1sGb1sdCsdAsdTsdTsdAsdAsdTsdAsdAsAb1sGb1sTb1sGb1 290a C*b1sAb1sGb1sGb1sC*b1sdAsdTsdTsdAsdAsdTsdA*sdAsAb1sGb1sTb1sGb1sC*b1 290b C*b1sAb1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1sC*b1 290c C*b1sAb1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsTb1sGb1sC*b1 290d C*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1sC*b1 290e C*b7sAb7sGb7sGb7sC*b7sdA*sdTsdTsdAsdAsdTsdAsdAsdAsdGsdTsdGsC*b7 290f C*b4Ab4Gb4Gb4sdCsdAsdTsdTsdAsdAsdTsdA*sdAsAb4Gb4Tb4Gb4C*b4 290g C*b1ssAb1ssGb1ssdGssdC*ssdAssdTssdTssdA*ssdAssdTssdA*ssdAssdA*ssdGssTb1ssGb1ssC*b1 290h C*b2Ab2Gb2dGdC*dAdTdTdAdAdTdAdAAb2Gb2Tb2Gb2C*b2 290i C*b1Ab1dGdGdC*dA*dUdUdAdAdUdA*dA*Ab1Gb1Tb1Gb1C*b1 291a Ab1sC*b1sAb1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsAb1sGb1sTb1sGb1sC*b1 291b Ab1sC*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsTb1sGb1sC*b1 291c Ab4sC*b4sdAsdGsdGsdC*sdAsdTsdTsdAsdAsdUsdAsdAsdAsGb4sTb4sGb4sC*b4 291d Ab1sdC*sdAsdGsdGsdC*sdA*sdTsdTsdAsdAsdTsdAsdAsAb1sGb1sTb1sGb1sC*b1 291e Ab2ssC*b2ssAb2ssGb2ssGb2ssdCssdAssdTssdTssdAssdAssdTssdAssdAssdAssdGssdTssGb2ssC*b2 291f Ab6C*b6Ab6Gb6Gb6dC*dAdTdTdAdAdTdAdAAb6Gb6Tb6Gb6C*b6 292a Ab1sC*b1sAb1sGb1sGb1sdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb1sTb1sGb1sC*b1sAb1 292b Ab2sC*b2sAb2sdGsdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsGb2sTb2sGb2sC*b2sAb2 292c Ab1sdC*sdAsdGsdGsdC*sdAsdUsdUsdAsdAsdUsdAsdAsdAsGb1sTb1sGb1sC*b1sAb1 292d Ab4sC*b4sAb4sGb4sdGsdCsdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsTb4sGb4sC*b4sAb4 292e Ab1C*b1Ab1dGdGdC*dAdTdTdAdAdTdAdAdAdGTb1Gb1C*b1Ab1 293a Tb1sAb1sC*b1sAb1sGb1sdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsTb1sGb1sC*b1sAb1sAb1 293b Tb1Ab1C*b1Ab1Gb1dGdC*dAdTdTdAdAdTdAdAdAdGTb1Gb1C*b1Ab1Ab1 293c Tb6sAb6sC*b6sdAsdGsdGsdCsdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsTb6sGb6sC*b6sAb6sAb6 294a Ab1sTb1sAb1sC*b1sAb1sdGsdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsdTsGb1sC*b1sAb1sAb1sAb1 294b Ab1Tb1Ab1C*b1Ab1dGdGdC*dAdTdTdAdAdTdAdAdAdGdTGb1C*b1Ab1Ab1Ab1 295a Tb1sAb1sTb1sAb1sC*b1sdAsdGsdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsdTsdGsC*b1sAb1sAb1sAb1sTb1 295b Tb1Ab1Tb1Ab1C*b1dAdGdGdC*dAdTdTdAdAdTdAdAdAdGdTdGC*b1Ab1Ab1Ab1Tb1 236a Ab1sTb1sAb1sTb1sAb1sdC*sdAsdGsdGsdC*sdAsdTsdTsdAsdAsdTsdAsdAsdAsdGsdTsdGsdC*sAb1sAb1sAb1sTb1sGb1 236b Ab1Tb1Ab1Tb1Ab1dC*dAdGdGdCdAdTdTdAdAdTdAdAdAdGdTdGdC*Ab1Ab1Ab1Tb1Gb1
11. Антисмысловой олигонуклеотид по любому из пп.1-10 для стимуляции регенерации и функционального восстановления поврежденных нервных путей и/или для лечения и компенсации индуцированного возрастом снижения обновления нейрональных стволовых клеток.
12. Антисмысловой олигонуклеотид по любому из пп.1-10 для применения в профилактике и лечении нейродегенеративных заболеваний, нейровоспалительных расстройств, травматических или посттравматических расстройств, нейрососудистых расстройств, гипоксических расстройств, постинфекционных расстройств центральной нервной системы, фиброзных болезней, гиперпролиферативных заболеваний, рака, опухолей, пресбиакузиса и пресбиопии.
13. Антисмысловой олигонуклеотид для применения по п.12, где нейродегенеративные заболевания и нейровоспалительные расстройства выбраны из группы, состоящей из: болезни Альцгеймера, болезни Паркинсона, болезни Крейтцфельдта-Якоба, нового варианта болезни Крейтцфельдта-Якоба, болезни Галлервордена-Шпатца, болезни Гентингтона, мультисистемной атрофии, деменции, лобно-височной деменции, расстройств двигательного нейрона, бокового амиотрофического склероза, спинномозговой мышечной атрофии, спиноцеребеллярных атрофий, шизофрении, аффективных расстройств, большого депрессивного расстройства, менингоэнцефалита, бактериального менингоэнцефалита, вирусного менингоэнцефалита, аутоиммунных расстройств ЦНС, рассеянного склероза, острых ишемических/гипоксических поражений, травмы центральной нервной системы и спинного мозга, травмы головы и позвоночника, черепно-мозговых травм, артериосклероза, атеросклероза, микроангиопатической деменции, болезни Бинсвангера, дегенерации сетчатки, улитковой дегенерации, дегенерации желтого пятна, улитковой глухоты, деменции, связанной со СПИДом, пигментного ретинита, Х-сцепленного рецессивного синдрома тремора/атаксии, прогрессирующего супрануклеарного паралича, стриатонигральной дегенерации, оливопонтомозжечковой дегенерации, синдрома Шая-Дрейджера, зависящего от возраста дефицита памяти, неврологических расстройств развития, связанных с деменцией, синдрома Дауна, синуклеинопатий, мутаций супероксиддисмутазы, расстройств повторов тринуклеотида, травмы, гипоксии, сосудистых заболеваний, сосудистых воспалений и старения ЦНС, и где фиброзные болезни выбраны из группы, состоящей из: фиброза легких, кистозного фиброза, цирроза печени, эндомиокардиального фиброза, «старого» инфаркта миокарда, фиброза предсердий, фиброза средостения, миелофиброза, забрюшинного фиброза, прогрессирующего массивного фиброза, нефрогенного системного фиброза, болезни Крона, келоида, системного склероза, артрофиброза, болезни Пейрони, контрактуры Дюпюитрена и остаточных явлений после красной волчанки.
14. Фармацевтическая композиция, содержащая, по меньшей мере, один антисмысловой олигонуклеотид по любому из пп.1-10 вместе, по меньшей мере, с одним фармацевтически приемлемым носителем, эксципиентом, адъювантом, растворителем или разбавителем.
RU2017120481A 2014-11-16 2015-11-16 Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r RU2717454C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14193368.9A EP3020813A1 (en) 2014-11-16 2014-11-16 Antisense-oligonucleotides as inhibitors of TGF-R signaling
EP14193368.9 2014-11-16
PCT/EP2015/076730 WO2016075339A1 (en) 2014-11-16 2015-11-16 Antisense-oligonucleotides as inhibitors of tgf-r signaling

Publications (3)

Publication Number Publication Date
RU2017120481A true RU2017120481A (ru) 2018-12-18
RU2017120481A3 RU2017120481A3 (ru) 2019-05-27
RU2717454C2 RU2717454C2 (ru) 2020-03-23

Family

ID=51900289

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017120481A RU2717454C2 (ru) 2014-11-16 2015-11-16 Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r

Country Status (22)

Country Link
US (4) US11213541B2 (ru)
EP (3) EP3020813A1 (ru)
JP (2) JP6832285B2 (ru)
KR (2) KR102310899B1 (ru)
CN (2) CN113151261A (ru)
AU (3) AU2015345006B2 (ru)
BR (1) BR112017006201B1 (ru)
CA (2) CA2964834C (ru)
CL (2) CL2017001233A1 (ru)
CY (1) CY1121110T1 (ru)
DK (1) DK3218488T3 (ru)
ES (1) ES2705066T3 (ru)
HU (1) HUE041793T2 (ru)
IL (2) IL251565B (ru)
MX (2) MX2017006369A (ru)
MY (1) MY181404A (ru)
PL (1) PL3218488T3 (ru)
PT (1) PT3218488T (ru)
RU (1) RU2717454C2 (ru)
SG (1) SG11201703127SA (ru)
TR (1) TR201900844T4 (ru)
WO (1) WO2016075339A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
WO2019010226A1 (en) * 2017-07-03 2019-01-10 The Regents Of The University Of California CHEMICALLY MODIFIED MICROARN-214 ANTISENS AND USE THEREOF FOR THE TREATMENT OF HEMORRHAGIC RECTOCOLITE AND PROCTITE
EP4092118A1 (en) * 2017-12-22 2022-11-23 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
AU2018386527A1 (en) * 2017-12-22 2020-04-30 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
WO2019122279A1 (en) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
EP4237436A2 (en) * 2020-10-29 2023-09-06 Mariano A. Garcia-Blanco Soluble interleukin-7 receptor (sil7r) modulating therapy to treat cancer
CN114588160A (zh) * 2020-12-07 2022-06-07 四川大学华西医院 具有抗肺纤维化作用的次黄碱衍生物
CN113992687B (zh) * 2021-12-28 2022-04-08 浙江宇视科技有限公司 智能业务集群调度方法、装置、电子设备及存储介质

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU722735B2 (en) 1996-02-19 2000-08-10 Nycomed Imaging As Thermally stabilized contrast agent
US20030064944A1 (en) * 2001-06-21 2003-04-03 Isis Pharmaceuticals Inc. Antisense modulation of transforming growth factor beta receptor II expression
EP2141233B1 (en) 2002-11-18 2016-10-19 Roche Innovation Center Copenhagen A/S Antisense design
JP2007502284A (ja) * 2003-08-13 2007-02-08 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ siRNAによるTGFベータII型受容体発現のサイレンシング
ZA200606460B (en) * 2004-02-09 2008-02-27 Regenion Gmbh Inhibitors of TGF-R signaling for treatment of CNS disorders
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007112753A2 (en) 2006-04-03 2007-10-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
JP5441688B2 (ja) 2006-05-11 2014-03-12 アイシス ファーマシューティカルズ, インコーポレーテッド 5’修飾二環式核酸類似体
EP2090127A2 (en) 2006-10-30 2009-08-19 Nokia Corporation Method, apparatus and system providing operator controlled mobility for user equipment
WO2008109546A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tgfbr gene expression and uses thereof
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
CN102089429A (zh) * 2008-07-15 2011-06-08 弗·哈夫曼-拉罗切有限公司 用于抑制TGF-β受体基因表达的组合物和方法
NZ598943A (en) * 2009-10-16 2014-09-26 Glaxo Group Ltd Hbv antisense inhibitors
AU2011263642B2 (en) * 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
US9115371B2 (en) * 2011-08-18 2015-08-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
CN104004762B (zh) * 2014-05-20 2016-03-30 南京医科大学附属南京儿童医院 Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling

Also Published As

Publication number Publication date
JP6983343B2 (ja) 2021-12-17
IL269151B2 (en) 2023-08-01
KR102417601B1 (ko) 2022-07-05
MX2020011476A (es) 2020-12-07
US20220143071A1 (en) 2022-05-12
KR20210113697A (ko) 2021-09-16
US10363266B2 (en) 2019-07-30
CA3201845C (en) 2024-02-20
RU2017120481A3 (ru) 2019-05-27
EP3218488B1 (en) 2018-10-24
CN107002082B (zh) 2021-02-02
EP3218488A1 (en) 2017-09-20
RU2717454C2 (ru) 2020-03-23
KR102310899B1 (ko) 2021-10-12
CY1121110T1 (el) 2019-12-11
JP2018501816A (ja) 2018-01-25
CA2964834C (en) 2023-08-08
DK3218488T3 (en) 2019-01-14
IL269151A (en) 2019-11-28
AU2015345006A1 (en) 2017-06-08
JP2021072841A (ja) 2021-05-13
BR112017006201A2 (pt) 2018-05-02
CL2019000980A1 (es) 2019-07-12
HUE041793T2 (hu) 2019-05-28
KR20170095230A (ko) 2017-08-22
CA3201845A1 (en) 2016-05-19
EP3418385A1 (en) 2018-12-26
WO2016075339A1 (en) 2016-05-19
CA2964834A1 (en) 2016-05-19
AU2020260380B2 (en) 2023-04-13
IL269151B1 (en) 2023-04-01
CN113151261A (zh) 2021-07-23
AU2015345006B2 (en) 2020-11-05
US20170319614A1 (en) 2017-11-09
MX2017006369A (es) 2018-02-16
IL251565B (en) 2020-05-31
ES2705066T3 (es) 2019-03-21
IL251565A0 (en) 2017-05-29
BR112017006201B1 (pt) 2023-04-18
SG11201703127SA (en) 2017-06-29
US20190314401A1 (en) 2019-10-17
EP3020813A1 (en) 2016-05-18
AU2020257116B2 (en) 2023-01-12
US20160138029A1 (en) 2016-05-19
AU2020257116A1 (en) 2020-11-19
PL3218488T3 (pl) 2019-04-30
CN107002082A (zh) 2017-08-01
MY181404A (en) 2020-12-21
TR201900844T4 (tr) 2019-02-21
PT3218488T (pt) 2019-01-21
JP6832285B2 (ja) 2021-02-24
CL2017001233A1 (es) 2017-12-15
AU2020260380A1 (en) 2020-11-19
US11213541B2 (en) 2022-01-04

Similar Documents

Publication Publication Date Title
RU2017120481A (ru) Антисмысловые олигонуклеотиды в качестве ингибиторов сигнального пути tgf-r
US20240035032A1 (en) Oligomers and oligomer conjugates
US20160108396A1 (en) Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
JP6027542B2 (ja) 非コード免疫調節性dna構築物
CA2866392C (en) Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
JP2022062143A (ja) 腎臓病の処置のための組成物と方法
US20100215646A1 (en) Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo) containing different lengths of palindromic segments
EP2920308A1 (en) Cancer treatment
JP2018512127A5 (ru)
CA2578775A1 (en) Methods and compositions for inhibition of innate immune responses and autoimmunity
JP7155302B2 (ja) Atxn3を標的とするアンチセンスオリゴヌクレオチド
US20240150758A1 (en) Use of fubp1 inhibitors for treating hepatitis b virus infection
WO2016019063A1 (en) Compositions and methods for modulating tau expression
US20190345495A1 (en) Antisense oligonucleotides for modulating nfkb2 expression
JP2011505798A (ja) Mcl−1を調節するためのRNAアンタゴニスト化合物
US20200216845A1 (en) Antisense oligonucleotides for modulating rela expression
CN220699235U (zh) 一种金刚石树脂布拉磨块
WO2020007889A1 (en) Antisense oligonucleotides targeting stat1
WO2020007772A1 (en) Antisense oligonucleotides targeting gbp-1